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The adenosinergic pathway plays a critical role in cancer development and 
progression, as well as in drug resistance to chemotherapy and/or targeted-
therapy. 
The goal of this PhD thesis was to investigate and fully characterize the role of 
CD73/adenosine A2A-A2B receptors axis in cancer, highlighting the therapeutic 
potential of inhibitors of the adenosinergic pathway.  
We firstly characterized the mechanism/s by which A2BR promotes 
immunosuppression and angiogenesis in tumor-bearing hosts, focusing on the role 
of myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts 
(CAFs). The results revealed that treatment of melanoma-bearing mice with 
Bay60-6583, a selective A2BR agonist, is associated with 1. increased tumor 
VEGF-A expression and vessel density, and 2. increased accumulation of tumor-
infiltrating CD11b+Gr1+cells (MDSCs). MDSCs strongly contribute to the 
immunosuppressive and angiogenic effects of Bay60-6583. Melanoma-bearing 
mice treated with a selective A2BR antagonist PSB1115 showed reduced tumor 
growth compared to controls and this effect was associated with reduced tumor 
angiogenesis, low levels of MDSCs and increased number of tumor-infiltrating 
CD8+ T cells. Furthermore, blockade of A2BR increased the anti-tumor effects of 
VEGF-A inhibitors. Next, we verified that A2BR activation also drives fibroblasts 
activation within melanoma tissues, by increasing the number of FAP positive 
cells within tumor lesions. FAP is a common marker of activated fibroblasts also 
named cancer-associated fibroblasts. These cells produce and secrete various 
tumor-promoting factors, including fibroblast growth factor (FGF)-2 and 
CXCL12 or stromal-derived factor 1 α (SDF1α), that were increased both in 
melanoma tissue and fibroblasts isolated from melanoma tissue or from skin upon 
Bay60-6583 treatment. Bay60-6583-induced FGF-2 from fibroblasts contributed 
to melanoma cells proliferation. The CXCL12/CXCR4 pathway, instead, was 
involved in the pro-angiogenic effects of A2BR agonist, but not in its 
immunosuppressive effects. These effects were significantly blocked by the A2BR 
antagonists PSB1115. Taken together, these data elucidate the pivotal role of 
	
A2BR in establishing a positive cross-talk between tumor-infiltrating immune 
cells, fibroblasts and endothelial cells that sustain tumor growth, reinforcing the 
therapeutic potential of A2BR blockers for cancer therapy. 
We next investigated the immunosuppressive mechanism mediated by A2AR that 
occurs through the Notch signalling pathway in CD8+ T cells. A2AR stimulation 
with CGS-21680 downregulated Notch1 expression in CD3/CD28-stimulated 
CD8+ T cells at the protein level but not at transcriptional level. The inhibitory 
effects of CGS-21680 on effector functions of CD8+ T cells were enhanced in 
presence of the Notch1 inhibitor, PF-03084014. Similar results were obtained also 
in CD8+ T cells treated with forskolin, an activator of adenylate cyclase, which 
mimics the effects of CGS-21680. The A2AR agonist did not influence the 
expression of Notch1 in CD8+ T cells after TCR activation, suggesting that 
stimulation of A2AR affects the expression of TCR-induced Notch expression. 
These results were confirmed by using transgenic CD8+ T cells from N1IC mice 
(N1IC CD8+ T cells) that were less sensitive to the inhibitory effects of CGS-
21680. CD8+ T cells deficient of A2ARs were instead sensitive to the inhibitory 
effects of the Notch inhibitor PF-03084014. Overall, our results indicate that the 
inhibitory effects of adenosine via A2A receptor occurs, at least in part, by 
reducing the Notch1 expression and activity, by blocking the TCR-mediated 
signalling transduction in CD8+ T cells. 
Finally, we evaluated the associations of soluble CD73 (sCD73) enzyme activity 
with clinical outcomes of patients with metastatic melanoma receiving the anti-
PD1 agent nivolumab. In a retrospective study we found that melanoma patients 
stage IV with high basal serum level of sCD73 enzyme activity, before starting 
nivolumab treatment, had a lower response rate to nivolumab, shorter survival and 
higher rates of progression of disease. Patients obtaining partial response to 
nivolumab or stable disease had low levels of sCD73 activity in the serum, thus 
suggesting a predictive role of response to nivolumab therapy for sCD73. This 
evidence could be very helpful to select patients to an appropriate therapy and 
then, neutralizing CD73 with clinically validated CD73 monoclonal antibodies 
could represent a highly potent and innovative therapy in combination regimen. 
 
	
In conclusion, we provide new insights into the mechanisms by which 
adenosinergic molecules modulate immune- and stromal-cells responses in the 
tumor environment, that is important for developing combination strategies for 
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 1.1 Role of adenosine in cancer: an overview 
 
Adenosine is a purine nucleoside involved in the regulation of several 
homeostatic mechanisms (1). In physiological conditions, adenosine is mainly 
produced at the intracellular level by S-adenosyl-homocysteine through the S-
adenosyl-homocysteine hydrolase (SAH); while, in pathological conditions, its 
synthesis occurs at the extracellular level starting from ATP by two ectoenzymes, 
the ecto-nucleoside triphosphate diphosphohydrolase-1 (CD39) and the ecto-5’- 
nucleotidase (CD73) expressed on both hematopoietic and non- hematopoietic 
cells (Figure 1.1) (2, 3).  




Figure 1.1: Adenosine synthesis in physiological conditions by S-adenosyl-
homocysteine hydrolase-SAH and in pathological conditions mainly by two 
ectoenzymes, ecto-5’- nucleotidase (CD73) and ectonucleoside triphosphate 
diphosphohydrolase-1 (CD39). [Modified by Krysko et al., 2012_ (4)]. 
 
 
Once released in the extracellular space, adenosine elicits its functions by binding 
Physiological conditions Pathological conditions 
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to one of the four membrane adenosine receptors (A1, A2A, A2B, A3) which contain 
seven transmembrane domains coupled to G proteins (5). Thus, adenosine can 
inhibit (via A1 and A3) or stimulate (via A2A and A2B) the adenylyl cyclase 
resulting in a decrease or increase in cyclic AMP (cAMP) accumulation, 
respectively (Figure 1.2) (6). 
 
 
        
 
 
Figure 1.2: A schematic illustrating the adenosine biosynthesis and the 
catabolism and its interaction with the four membrane adenosine receptors (A1, 
A2A, A2B, A3) (1). 
 
 
In response to tissue injury, ATP is strongly released from stressed, damaged 
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and/or tumor cells and it is rapidly converted in ADP and AMP through two 
reversible steps via CD39; then AMP is irreversible degraded into adenosine by 
CD73 (3) (Figure 1.2). Under homeostatic conditions extracellular adenosine level 
is low, while during pathophysiological events (including stress, infection, 
inflammation and cancer) extracellular adenosine levels can be increased from 10-
200 nmol/L up to 10-100 µmol/L (7). In contrast to ATP, adenosine is a potent 
immunosuppressive and anti-inflammatory mediator. These latter effects are 
mainly mediated by cAMP-elevating adenosine A2A and/or A2B receptors. In the 
context of cancer, adenosine within tumor microenvironment potently suppresses 
anti-tumor T-cell responses promoting tumor growth (8). Indeed, the 
adenosinergic pathway represents one of the major immunosuppressive 
mechanism within the tumor microenvironment, that could also potentially limit 
the therapeutic success of existing and new immunotherapeutic agents. 
Importantly, the expression of adenosine-generating enzymes and adenosine 
receptor subtypes can be regulated within tumor microenvironment by many 
factors and their expression often correlates with poor prognosis in patients with 
cancer. For example, inflammatory mediators, hypoxia and genetic drivers can 
up-regulate adenosine signalling pathway (8) (Figure 1.3). In particular, hypoxia 
within tumor microenvironment is one of the main factors responsible of the 
increased production of adenosine in many solid tumors. Indeed, CD39 and CD73 
expression increases under hypoxic conditions, while the expression of the 
adenosine kinase, which inhibits the metabolism of adenosine, is down-regulated 
(9). At the same time, the expression of A2AR and A2BR is also up-regulated (10). 
Consequently, adenosine along with other HIF-induced immunosuppressive 
factors and cells, contributes to modulate the functions of tumor cells, tumor-






Figure 1.3: Main factors that influence the expression of adenosine receptors 
within tumor microenvironment (8). 
 
A large number of pre-clinical studies indicate that selective adenosine receptor 
antagonists or inhibitors of adenosine-generating enzymes induce effective anti-
tumor immune responses, and some of them represent new attractive therapeutic 
agents for cancer therapy, recently included in clinical trials in patients with 
malignancies (8). 
 
In the following paragraph the main objectives of this PhD thesis are summarized 




1.2 Aim of the PhD project and specific objectives 
 
 Targeting adenosine signalling pathway with specific inhibitors could 
effectively suppress tumor progression and metastases through multiple 
mechanisms (1). CD73-generating adenosine and their receptors A2A and A2B 
affect the behaviour of multiple cell populations within tumor microenvironment. 
In addition, recent evidence indicate that adenosine signalling pathway can be 
regulated in response to immunotherapy or targeted-therapy, including anti-PD1 
agents, T-cell therapy or BRAF/MEK inhibitors in cancer patients (11, 12). 
Therefore, understanding the mechanisms by which adenosinergic molecules 
modulate immune- and stromal-cells responses in the tumor environment is 
important for developing combination therapies. Furthermore, evaluating the 
adenosinergic-targeted molecules before treatment with currently used 
immunotherapies, such as anti-PD1 agents, and how they relate to response is of 
interest in clinical practice.   
 
For this purpose, the specific objectives of this project were: 
 
1) To evaluate the role of A2B receptor in tumor and surrounding stroma in a 
mouse model of melanoma 
Background and rationale. Over the years, A2BR has been the less 
characterized receptor among adenosine receptor subtypes, due to its low 
expression in physiological conditions and low adenosine affinity. However, 
emerging evidence suggest that A2BR may play a pivotal role in adenosine-
mediated tumor progression (13, 14) because of high adenosine levels and/or 
increased A2BR expression on many cell types. Indeed, A2BR is the main 
adenosine receptor subtype expressed on myeloid cells and it may play a role in 
promoting tumor proliferation, metastases, immunosuppression and angiogenesis 







Figure 1.1.1: A2BR pathway is involved in several functions on different cell 
types within tumor microenvironment (14). 
Targeting the A2BR has proved to be therapeutically effective in some murine 
tumor models (14), but the mechanisms of these effects are still incompletely 
understood.  
Here, we evaluate the effects of pharmacological A2BR modulators in a mouse 
melanoma model, evaluating:  
1.1 the role of myeloid-derived suppressor cells (MDSCs) in the pro-
angiogenic effects of A2BR and whether blockade of A2BR with selective 
antagonists could enhance the efficacy of anti-VEGF treatment;  
1.2 the role of A2BR in modulating the activity of cancer-associated 
fibroblasts (CAFs).  
 
2) To study the Notch1-A2AR cross-talk in murine activated CD8+ T cells.  
Background and rationale. A2AR is the main adenosine receptor subtype 
expressed on lymphoid cells (15). Stimulation of A2AR on CD8+ T cells potently 
suppresses the TCR-mediated proliferation and activation in a cAMP-dependent 
manner (Figure 1.1.2) (16). A2AR activation is also able to inhibit the functions of 
innate and adaptive immune cells, other than CD8+ T cells (17); consequently, 
A2AR blockade has been advocated to facilitate tumor immunotherapy.  
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T cells are essential effectors of tumor immunity (18). One of the crucial 
signalling pathways involved in T-cell development, lineage selection and 
activation is Notch. Recent studies highlight the pivotal role of Notch signalling in 
the differentiation and function of several T cell subsets (19). It is well 
documented that Notch is activated after T-cell receptor (TCR) engagement (20) 
and that Notch signalling is required for T-cell activation and for the cytotoxic 
activity of CD8+ T cells. Notch1 is also required for the differentiation of CD8+ T 
effector cells (21) and constitutive expression of active Notch1 renders CD8+ T 
cells resistant to the immune suppressive activity of MDSCs (22).  
 
          
 
 
Figure 1.1.2: A2AR pathway in T cells; interaction with the early events upon T 
cell receptor (TCR) activation (23). 
 
Thanks to the collaboration with Dr. Lucio Miele at the Stanley S. Scott Cancer 
Center (Louisiana State University Health Science Center_LSUHSC) I could 
work in his Laboratory in order to further investigate the mechanism/s through 
which A2AR suppresses the functions of activated CD8+ T cells, we evaluated the 
Notch1 signalling pathway upon A2AR stimulation.  
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3) To measure soluble CD73 levels in the peripheral blood of patients with 
advanced melanoma receiving nivolumab as potential biomarker of response 
to immunotherapy 
Background and rationale. Pre-clinical data suggest that high expression 
of CD73 in cancer is associated to a reduced effectiveness of therapies with anti-
PD1 (24). CD73 is highly expressed in different types of tumors in patients and 
often its expression correlates with poor prognosis and/or resistance to 
conventional therapies (24). Nowadays, specific inhibitors of CD73 entered 
clinical trials in patients with malignancies, alone or in combination with anti-
PD1 agents (8). Here, we proposed to measure the CD73 activity in the peripheral 
blood of patients with metastatic melanoma before receiving the anti-PD1 agent, 
nivolumab, in order to evaluate the potential predictive value of response to 
immunotherapy of CD73, and possible provide additional information to better 
select subsets of patients who will benefit from immunotherapies in combination 





















2.1 Role of A2BR in tumor and surrounding stroma 
 
2.1.1 A2BR expression and transduction 
A2BR is largely expressed in our organism. As explained in Chapter 1, A2BR binds 
adenosine with a lower affinity than A2AR (A2BR-EC50 is 24 µmol/L). Therefore, 
its signalling capacity depends on the adenosine concentration as well as on its 
density on the cell surface. The expression of A2BR on cells is influenced by 
metabolic, inflammatory and hormonal factors including adenosine itself. A2BR 
expression is transcriptionally regulated through the oxygen-regulated 
transcription factor hypoxia inducible factor (HIF-1 α) (25). As illustrated in 
Figure 2.1.1, A2BR couples to both Gs and Gq proteins but the most studied 
intracellular signalling pathway is the Gs-mediated signalling, that increased 
cAMP levels leading to activation of to the cAMP-dependent protein kinase PKA.  
Moreover, A2BR activates the mitogen activated protein (MAP) kinase signalling 
(26). 
 
         
                   
        Figure 2.1.1_ A2BR signalling transduction. 
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2.2.2 A2BR in cancer 
A2BR is important in some pathophysiological conditions, including vascular 
injury (27), chronic lung disease (28), vascular leak (29), and ischemic disease 
(30). Recent evidence show that A2BR plays an important role in mediating also 
the pro-tumor effects of adenosine. Ryzhov and collaborators (13) in 2008 
provided the first genetic evidence for a pivotal role of A2BR in tumor 
progression, showing that tumor growth in A2BR deficient mice was reduced 
compared to that observed in wild type mice. A number of studies indicate that 
A2BR can directly affect the proliferation/migration of tumor cells and the 
function of tumor-infiltrating immune cells and other stroma cells that populate 
the tumor niche, including endothelial cells (Reviewed in Ref 14). A2BR may 
influence the features of some immune cell populations, including Treg cells and 
dendritic cells (31, 32) and some experimental evidence in tumor mouse models 
suggest that the selective blockade of A2BR may ameliorate T cell-mediated 
immune surveillance by impairing the accumulation of suppressive cells and the 
levels of inflammatory factors in the tumor microenvironment (13, 33-35). 
Despite these evidence, further studies are needed to better investigate thoroughly 
the mechanisms by which blockers of this receptor limit tumor growth. 
Understanding the relative role of A2B receptor in tumor, depending on the cell 
types, on its distribution and expression, will help to potentially apply A2BR-
targeted agents for cancer treatment. 
 
2.1.3 A2BR and MDSCs 
A2BR has been detected on several immune cell populations such as mast cells 
(36), neutrophils (29), dendritic cells (32), macrophages (37), lymphocytes (38) 
and on immune suppressive cells such as MDSCs (39). MDSCs are a 
heterogeneous population of immature myeloid cells expressing CD11b and Gr1 
and their accumulation can be considered as a hallmark of chronic inflammation 
leading to T cells suppression through different mechanisms. This cell population 
is made up of myeloid progenitor cells and immature myeloid cells (IMCs). 
Normally IMCs, generated in the bone marrow, differentiate into mature 
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granulocytes, macrophages or dendritic cells but in pathological condition 
(infection, sepsis, trauma, cancer) IMCs undergo a block in their differentiation 
and an upregulation of their immune suppressive factors such as arginase1, 
inducible nitric oxide synthase (iNOS), nitric oxide (NO) and reactive oxygen 




Figure 2.1.2_ a) Generation of MDSCs from their bone marrow’s progenitors b) 
in both normal and pathological conditions (40). 
 
MDSCs-mediated immunosuppressive activity needs a direct contact between 
cells suggesting that these cells act through both membrane receptors and the 
release of short-lived soluble factors (41). MDSCs play a critical role in leading 
immunosuppression acting as potent suppressors of T cell-mediated responses 
within tumor milieu, promoting tumor growth (42). Recent evidence suggest that 
the signal transducer and activator of transcription 3 (STAT3) could be the main 
transcription factor concerning MDSCs expansion (40, 41). The transcription 
factor STAT3 translocates into the nucleus where it directly binds to DNA 
sequences upon phosphorylation at tyrosine 705. In fact, STAT3 phosphorylation 
is significantly increased in IMCs from tumor-bearing mice compared to control 
mice (43). In addition, MDSCs produce pro-angiogenic factors such as VEGF-A, 
in a STAT3-dependent manner, stimulating tumor angiogenesis (44). VEGF-A is 
the most potent pro-angiogenic factor that induces proliferation, sprouting and 
tube formation of endothelial cells. Moreover, these pro-angiogenic factors can 
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themselves promote MDSCs accumulation in the tumor microenvironment 
creating a vicious circle (44). Ryzhov and colleagues demonstrated that the 
activation of A2BR promotes MDSCs expansion in vitro contributing to induce 
immunosuppression by producing adenosine (45). Moreover, A2BR deficient mice 
showed reduced amounts of CD11b+ Gr1+ cells suggesting that A2BR suppresses 
immune system activity (13). These and more other evidence, previously 
demonstrated in our laboratory, show that the selective A2BR blockade might 
improve T cell-mediated immune surveillance by impairing MDSCs accumulation 
within tumor microenvironment (34). Accordingly, our aim was to evaluate the 
role of MDSCs in the pro-angiogenic effects of A2BR and whether blockade of 
A2BR could enhance the efficacy of anti-VEGF treatment. 
 
2.1.4 A2BR and tumor-associated fibroblasts 
Tumor microenvironment is made up not only of tumor and immune suppressive 
cells but also of stroma cells that contribute to the release of inflammatory 
mediators including cytokines, chemokines and growth factors, which contribute 
to enhance tumor growth. As showed in Figure 2.1.3, stromal cells that 
characterize tumor milieu comprise endothelial cells, fibroblasts, inflammatory 
cells and extra-cellular matrix which communicate with neoplastic cells through 






Figure 2.1.3_ Adenosine synthesis and its functions on several cell populations 
[Modified fromVijayan et al., Nature, 2017 (8)]. 
 
One of the major component of tumor stroma are cancer associated fibroblasts 
(CAFs) that, together with other stromal cells, can both modulate tumor initiation 
and progression and induce drug resistance to chemotherapy and/or targeted-
therapy, in a soluble factor- and cell adhesion-manner (reviewed in references 46, 
47). Therefore, understanding thoroughly the mechanisms that regulate the 
interplay between stromal cells and neoplastic cells is of great interest. 
Fibroblasts are critical component of tumor stroma (10, 25, 48-51) and they are 
involved in tumor initiation and progression through the production of paracrine 
factors such as SDF-1 or FGF-2 (stromal derived factor-1 and fibroblast growth 
factor-2, respectively, which are both considered as markers of fibroblasts 
activation) (52). Activated fibroblasts are associated with tumor growth and 
angiogenesis (53). In fact, VEGF-A is released by cancer cells but also 
inflammatory cells (like MDSCs as described above) and fibroblasts contribute to 
VEGF-A release (44, 52). 
Previous data show that fibroblasts express adenosine receptors (10, 25, 48-51). 
Accordingly, our aim was to study the role of A2BR in the modulation of stromal 




2.2 Materials and Methods  
 
2.2.1 Cells, mice and treatments 
A murine melanoma cell line, B16-F10 from American Type Culture Collection 
(LGC Standards srl., Milan, Italy), was used to create a murine melanoma model 
for our studies. B16-F10 cells were cultured according to company’s instructions 
using DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FBS 
(Fetal Bovine Serum), 100 U/ml penicillin and 0.1 mg/ml streptomycin. A 
suspension of 2.5 × 105 cells in PBS (Phosphate-Buffered Saline) was injected s.c. 
(subcutaneously) into the right flank of C57Bl6j mice (6–8 week-old females) that 
were obtained from Charles River (Charles River, Lecco, Italy). All the 
experiments performed using mice were approved by Italian Health Ministry 
(protocol n° 12827) and conducted according to institutional animal care 
guidelines, Italian Law 26/2014 based on the European Community Law for 
Animal Care 2010/63/UE.  
On day 7, after melanoma cells injection, mice were randomly grouped and 
treated as follows: 
- Bay60-6583 (0.2 mg/kg) (34, 54, 55) a selective A2BR agonist or PSB1115 (1 
mg/kg) (34, 56, 57) a selective A2BR antagonist (both from Tocris, UK) were 
injected p.t. (peritumorally) every day to evaluate the effects of A2BR stimulation 
or A2BR blockade within tumor microenvironment, respectively. As control for 
Bay60-6583 was used phosphate-buffered solution (PBS) containing DMSO 
(0.1%).  
- 120 mg/kg gemcitabine (Sigma Aldrich, Milan, Italy) was administered i.p. 
(intraperitumorally) every three days until endpoint, to deplete MDSCs in mice 
(34, 58-60). 
- 50 µg of anti-VEGF A antibody (BioLegend, Campoverde, Milan, Italy) was 
administered i.p. every day for VEGF neutralization experiments, using isotype 
IgG as control. 
- S3I-201 (5 mg/kg) (Sigma Aldrich) was administered i.p. every two days until 
endpoint, to block STAT3 signalling (61-63).  




Tumor volume was monitored every two days during the treatment period using 
an electronical caliper and calculated as 4/3π × (long diameter / 2) × (short 
diameter / 2) (46). After one week of treatment mice were sacrificed and tumor 
tissues were harvested from each mouse for further analyses.  
 
2.2.2 Flow cytometry analysis 
Melanoma tissues were harvested from mice and digested with collagenase 1U/ml 
(Sigma Aldrich, Italy), passed through 70 µm cell strainers and red blood cells 
(RBC) were lysed. The single cell suspension obtained from each sample was pre-
incubated with anti-mouse CD16/CD32 (eBioscience, San Diego, CA, USA) to 
block non-specific Fc-mediated interactions. Antibodies against CD11c-FITC, 
CD11b-PeCy5.5, Gr1-PE or Gr1- allophycocyanin, CD3-PeCy5.5; CD8-
allophycocyanin or CD8-PE; CD4-allophycocyanin; NK1.1-PE (eBioscience and 
BioLegend) were used. Data were acquired with a FACSCalibur flow cytometer 
(BD Biosciences). 
 
2.2.3 Isolation of CD11b+ cells 
Melanoma tissues were collected aseptically and digested with collagenase 1U/ml. 
Cells were passed through 70 µm strainers, followed by RBC lysis. CD11b+ cells 
were isolated by positive magnetic kit (CD11b EasySep Isolation kit; Stem Cell 
Tech) according to manufacturer’s instruction. Purity of CD11b+ cells was 
checked by flow cytometry and it was around 90%.  
 
2.2.4 Fibroblasts isolation and treatments 
To investigate the role of A2BR in modulating the activity of stromal fibroblasts, 
we isolated fibroblasts from either melanoma or skin tissues. The culture medium 
used for these studies was RPMI 1640 supplemented with 1µg/L, 10% FBS, 100 
U/ml penicillin, 0.1 mg/ml streptomycin (Lonza, Milan, Italy).  
- To isolate cancer-associated fibroblasts, we collected the entire melanoma 
capsule aseptically and, after several washes with sterile PBS (Euroclone, Milan, 
Italy), we placed the capsule in a Petri dish with polylysine-coated surfaces.  
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- To isolate fibroblasts from the skin (64) we shaved C57Bl6j mice and aseptically 
harvested skin samples which were dissociated both mechanically by cutting the 
tissue into 1 mm pieces using a scalpel blade and enzymatically by using 1 U/ml 
collagenase A (Sigma-Aldrich, Milan, Italy). In both cases, the entire melanoma 
capsule and the digested skin fragments, were placed in a Petri dish with 
polylysine-coated surfaces using the supplemented RPMI medium described 
above and left for 5-7 days in a tissue culture incubator allowing fibroblasts to 
migrate from the tissue into the Petri dish. 
Isolated fibroblasts were treated with 1, 10 or 100 nM Bay60-6583 (A2BR agonist) 
for further analyses and 10 nM Bay60-6583 was chosen to perform in vitro 
experiments as it achieved optimal effects in preliminary studies. Moreover, A2BR 
antagonist, PSB1115 100 nM was used in some experiments. 
To mimic tumor microenvironment, skin isolated fibroblasts were exposed to 100 
µM CoCl2 used as hypoxia inducer (55) at different time points (0-24 hours). 
Fibroblasts exposed to hypoxia were also treated with 10 nM Bay60-6583 for 24 h 
for further analyses. Some experiments were also performed in presence of the 
A2AR agonist (1 µM) as described above. 
 
2.2.5 Western blot analysis 
Tumor tissues harvested from mice were homogenized in RIPA buffer (RIA 
Precipitation Buffer in which were freshly added 1mM Protease and Phosphatase 
Inhibitor Cocktail, 1 mM PMSF and 1 mM sodium orthovanadate), centrifuged 
and protein concentrations in supernatants were measured by Bio-Rad protein 
assay. Forty micrograms of total proteins were analysed by 10% denaturing 
polyacrylamide gels and then transferred electrophoretically to nitrocellulose 
membranes (Immobilon-NC, Millipore). Anti–VEGF (A-20) (Santa Cruz 
Biotechnology, DBA, Milan, Italy) and anti-tubulin (or anti-actin) (Sigma-
Aldrich) primary antibodies were used (Santa Cruz Biotechnology). VEGF-A 
expression was also measured in isolated CD11b+ cells.  
Isolated fibroblasts from tumor and/or skin were collected and suspended in RIPA 
buffer (Radio-Immuno Precipitation Assay Buffer in which were freshly added 
1mM Protease and Phosphatase Inhibitor Cocktail, 1 mM PMSF and 1 mM 
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sodium orthovanadate), centrifuged and protein concentrations in supernatants 
were measured by Bio-Rad protein assay. Forty micrograms of proteins were 
analysed by 10% denaturing polyacrylamide gels and transferred 
electrophoretically to PVDF membranes (Immobilon-NC, Millipore, Italy). 
Membranes were stained overnight at 4°C in humidified chamber with the 
primary antibodies that follows: 
- anti-A2BR (H-40) (clone N-19) (Santa Cruz Biotechnology); 
- anti-HIF1α (A300-286A) (Bethyl Laboratories, Tema Ricerca, Italy); 
- anti-CD73 (5NT5E, C-terminal) (Sigma-Aldrich, Milan, Italy). 
 
After 1 h at room temperature with the secondary antibodies, immunoreactive 
protein bands were detected by enhanced chemiluminescence reagents 
(Amersham Pharmacia Biotech, Buckinghamshire, UK) and analysed by Las4000 
(GE Healthcare Life Sciences). 
 
2.2.6 Immunofluorescence analysis by confocal microscopy 
Immunofluorescence analyses were performed on both melanoma frozen sections 
and isolated fibroblasts from tumor and/or skin. Tumor tissues were fixed with 
0.5% neutral buffered paraformaldehyde at 4°C for 2 hours and then incubated 
with 15% sucrose at 4°C overnight. Fixed samples were later frozen in Optimum 
Cutting Temperature (OCT) medium (Pella, Milan, Italy) and 10–20 µm thick 
sections were cut. To reduce nonspecific binding sites, slides were blocked in 
PBS with 20% normal goat serum (GIBCO BRL) or 5% Bovine Serum Albumin 
(BSA) containing 0.5% TritonX-100 for 30 minutes at room temperature. As far 
as isolated fibroblasts plated on poly-lysine-coated slides, after two washes in 
PBS they were fixed in 4% PFA, and nonspecific binding sites were blocked 
using 20% goat serum or 5% bovine serum albumin (BSA) for 30 minutes at 
room temperature, as appropriate. In both cases, slides were stained overnight at 
4°C in humidified chamber with the primary antibodies and 2 h at room 
temperature with the secondary antibodies.  The following antibodies were used:  
- VEGF (A-20) (1:100; Santa Cruz Biotechnology), detected with Alexa Fluor® 
488 Goat Anti-Rabbit IgG (H+L) (1:1000) secondary antibodies; 
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- FITC anti-mouse CD31 (MEC 13.3) (1.100, BioLegend); 
- Gr1 (Ly-6G, clone RB6–8C5) (1:100; eBioscience), (1:200; Abcam, Cambridge, 
UK), detected with Alexa Fluor® 555 Goat Anti-Rat IgG (H+L) (1:1000) (Life 
Technologies, Italy) secondary antibodies; 
- A2BR (N-19) (1:50; Santa Cruz Biotechnology), detected with DyeLightTM 549-
conjugated AffinePure Donkey anti-goat IgG (H+L) or DyeLightTM 488-
conjugated AffinePure Donkey anti-goat IgG (H+L) (Jackson Immunoresearch 
Laboratories Inc.) secondary antibodies; 
- FAPα (H-56) or FGF-2 (147) (1:100; Santa Cruz Biotechnology) were detected 
with Alexa Fluor® 488 or 555 Goat Anti-Rabbit IgG (H+L) (1:5000) secondary 
antibodies (Life Technologies, Italy);  
- CXCL12 (1:100; Santa Cruz Biotechnology) (clone P-159X) was detected with 
the secondary antibody Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) (1:5000);  
- Vimentin (E-5) (1:500; Santa Cruz Biotechnology) or fibronectin (A17) (1:200; 
Abcam) were detected with the secondary antibody Alexa Fluor® 555 Goat Anti-
Mouse IgG (H+L) (1:5000);  
- CXCR4 (clone L276F12) (1:100; BioLegend) was detected with Alexa Fluor® 
555 Goat Anti-Rat IgG (H+L) (1:5000). 
Slides were incubated overnight with primary antibodies in a humidified chamber 
at 4°C and with the secondary antibody for 2 hours at room temperature. DAPI 
was used to counterstain nuclei. In all staining experiments, isotype-matched IgG 
and omission of the primary Ab was used as controls. Slides were observed using 
a Zeiss LSM 710 Laser Scanning Microscope (Carl Zeiss MicroImaging GmbH). 
Samples were vertically scanned from the bottom of the coverslip with a 63x or 
40x (1.40 NA) Plan-Apochromat oil-immersion objective. Images were generated 
with Zeiss ZEN Confocal Software (Carl Zeiss MicroImaging GmbH). 
 
2.2.7 Proliferation assay 
96 well plates were used to culture melanoma-derived fibroblasts, B16-F10 cells 
or co-cultures of melanoma-derived fibroblasts and B16-F10 cells (1:1 ratio). 
Cells were treated with 10 nM Bay60-6583, 100 nM PSB1115 and/or both and 
cell proliferation assay was performed at 24-48-72 hours. 
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In some co-culture experiments was used an anti-FGF2 antibody at 100 ng/ml 
(recombinant FGF-β, Lonza, Italy, tested at the concentrations of 30-100 ng/ml) 
alone or in presence of 10 nM Bay60-6583. 
 
2.2.8 Elisa assay 
A mouse CXCL12/SDF-1 alpha ELISA kit (R&D Systems, Abingdon, UK) was 
used, according to manufacturer’s instruction, to determine the levels of CXCL12 
in the supernatant of isolated fibroblasts treated with 1, 10 or 100 nM Bay60-6583 
for 24 h with or without 100 nM PSB1115. 
 
2.2.9 Statistical analysis 
Data are from at least two-three independent experiments and results are 
expressed as mean ± SEM. Concerning immunofluorescence analysis, sections 
derived from tumors were obtained from at least 5-6 different mice per condition. 
Two sections were stained for each tumor and positive cells were counted in four-
to-five randomly selected fields per tumor section. The results of 
immunofluorescence in fibroblasts are expressed as mean (±S.E.M.) of 4 separate 
fibroblast preparations, each isolated from C57Bl6 mice. The optical density of 
the protein bands detected by Western blotting was performed with 
ImageQuantTL (Ge Healthcare). Data were analysed with GraphPad Prism 6 
(GraphPad Software). Two-tailed Student’s t test (2-group comparisons) or 
ANOVA (> 2-group comparisons) were performed as appropriate. P values < 0.05 






2.3.1 A2BR stimulation promotes tumor growth 
To evaluate the effects of A2BR stimulation in tumor-bearing mice we treated 
mice with a selective A2BR agonist Bay60-6583 seven days later B16-F10 
melanoma cells implantation. Mice treated with Bay60-6583 (0.2 mg/kg, p.t.) 
showed a significant increase in tumor volume compared with control mice 
(Figure 2.3.1), suggesting that A2BR has a pro-tumor role, in line with previous 
findings (39).  
 
                                 
Figure 2.3.1 Tumor growth monitored during the treatment with A2BR agonist. 
Data are from two independent experiments and represent mean ± SEM (n=9 per 
group). ***p<0.001. 
 
Notably, proliferation of B16-F10 melanoma cells was not affected by Bay60-
6583 treatment in vitro (data not shown) (39). 
 
 
2.3.2 A2BR stimulation enhances VEGF-A release in the tumor tissue 
Next we observed that VEGF-A expression was significantly increased in tumor 
tissues of mice treated with Bay60-6583 compared to controls (Figure 2.3.2 A). 
This effect was associated with an increased vessel density in Bay60-6583-treated 
mice compared to the vehicle (control mice), as assessed by staining melanoma 

























Moreover, while B16-F10 melanoma cells used in this model did not express 
VEGF-A, endothelial cells in the tumor tissue did express A2BR (Figure 2.3.2 C). 
Therefore, although we did not have a direct evidence on the role of A2BR on 
these cells in the tumor microenvironment, it is likely that stimulation of A2BR on 
endothelial cells could enhance the release of VEGF-A within tumor tissue (65, 
66). All these pro-tumoral effects mediated by Bay60-6583 treatments were 
partially inhibited by using an anti-VEGF A antibody (150 µg/mouse, i.p. every 
two days). Indeed, when VEGF-A was blocked with a specific antibody in 
melanoma-bearing mice, the pro-tumor activity of Bay60-6583 was significantly 
attenuated and the tumor growth was decreased (Figure 2.3.2 D). 
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Figure 2.3.2 A) VEGF-A expression in melanoma lysates harvested from mice 
treated with Bay60-6583 or vehicle (ctr). B) Immunofluorescence staining of 
CD31 and VEGF-A in melanoma sections of mice treated with Bay60-6583 or 
vehicle (ctr) and C) representative image of A2BR expression on CD31 positive 
cells in melanoma sections. Magnification 63x, scale bars represent 20µm. D) 
Tumor volume measured at day 14 after tumor cell injection of mice treated with 
Bay60-6583 or vehicle receiving anti-VEGF antibody or IgG. Data represented 
are from three different experiments and represent mean ±SEM (n=6-10 per 
group). *p<0.05, **p<0.01, ***p<0.001. 
 
Taken together, these results indicate that A2BR activation induces tumor 































2.3.3 MDSCs contribute to the angiogenesis mediated by A2BR stimulation 
We have previously demonstrated that stimulation of A2BR induces 
immunosuppression within tumor microenvironment, which favours tumor 
growth (34). Indeed, Bay60-6583-treated mice showed an increased accumulation 
of tumor-infiltrating MDSCs (identified as CD11b+Gr1+ cells) (Figure 2.3.3 A). 
This effect was associated to a significant reduction in the percentage of tumor-
infiltrating CD8+ T cells, NKT and NK1.1+ cells compared to control mice (34) 
(Figure 2.3.3 B). These results confirm that the activation of tumor A2BR 
modulates the presence of tumor-infiltrating immune cells and leads to 
immunosuppression and tumor growth.  
MDSCs are potent suppressor of T cells functions (40, 41) and they produce pro-
angiogenic factors, including VEGF-A (67-69). By means of immunofluorescence 
analysis, we showed that MDSCs in melanoma sections expressed VEGF-A 
(Figure 2.3.3 C) and also A2BR (Figure 2.3.3 D). Based on these results we 
hypothesized that MDSCs could contribute not only to the immunosuppression 
but also to angiogenic activities of Bay60-6583. Therefore, we first verified if the 
stimulation of A2BR could directly modulate the release of VEGF-A from 
MDSCs. Isolated splenic CD11b+ cells did express VEGF-A but there was no 
difference in VEGF-A expression levels in CD11b+ cells treated with Bay60-
6583 compared with control (data not shown) nor in CD11b+ cells isolated from 
Bay60-6583-treated mice compared with control mice (Figure 2.3.3 E). 
Nonetheless, tumor-infiltrating CD11b+Gr1+ cells were increased in Bay60-
6583-treated mice compared to control mice (34) (Figure 2.3.3 F). Therefore, to 
clarify the involvement of MDSCs in A2BR-mediated tumor angiogenesis, we 
treated mice with gemcitabine to deplete MDSCs in melanoma-bearing mice 
treated with Bay60-6583 or vehicle. Gemcitabine was administered in a single 
low dose, which did not significantly alter the percentage of CD3+, CD4+, CD8+ 
T cells and NK1.1+ cells in spleen or the viability of B16-F10 cells, but reduced 
significantly the percentage of MDSCs either in the tumor tissue (Figure 2.3.3 F) 
and in the spleen as we have previously demonstrated (34). Bay60-6583-treated 
mice receiving gemcitabine showed a significant reduction of VEGF-A 
expression in tumor tissue compared with control group (Figure 2.3.3 G). 
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Figure 2.3.3 A) Percentage of MDSCs in tumor tissues of mice treated with 
Bay60-6583 or vehicle (ctr). B) Percentage of tumor-infiltrating CD3+CD8+T 





































































Bay60-6583 or vehicle (ctr). C) Immunofluorescence staining of Gr1 and VEGF-
A and D) Gr1 and A2BR in melanoma sections. Magnification 63x, scale bars 
represent 20µm. E) VEGF-A expression analysed by Western blotting in CD11b+ 
cells isolated from melanoma sections harvested from mice treated with Bay60-
6583 or vehicle (ctr). F) Percentage of CD11b+Gr1+ cells in tumor tissues from 
mice treated with Bay60-6583, Gemcitabine, in combination or vehicle (ctr) and 
G) VEGF-A expression in melanoma sections obtained from mice treated as 
described above. Data represented are from three independent experiments and 
represent mean ±SEM (n=10 per group). *p<0.05, **p<0.01, ***p<0.001.  
 
These results indicate that the increased number of MDSCs induced by Bay60-
6583 contributes to produce VEGF-A within tumor microenvironment.  
 
 
2.3.4 Involvement of STAT3 in melanoma progression in Bay60-6583-treated 
mice 
Within tumor microenvironment, many signals can trigger VEGF-A expression 
and secretion, including STAT-3 (70, 71). Mechanistically, in Bay60-6583-treated 
mice, we observed an enhanced activation of STAT-3 since expression levels of 
phospho-(p)STAT3 increased compared to control mice (Figure 2.3.4 A). In 
melanoma-bearing mice, treated with the highly selective STAT3 inhibitor, S3I-
201, which preferentially inhibits STAT3 phosphorylation and STAT3 DNA-
binding activity (72-74), the expression of p-STAT3 significantly reduced (Figure 
2.3.4 B) as well as VEGF-A expression in melanoma tissue of Bay60-6583-
treated mice and control mice (Figure 2.3.4 C). These effects were associated with 
a strong inhibition of tumor growth in both groups (Figure 2.3.4 D).  
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Figure 2.3.4 A) and B) phospho-STAT3 (pSTAT3) expression analysis in tumor 
tissues from mice treated with Bay60-6583 or vehicle (ctr), receiving or not the 
STAT3 inhibitor S3I-201. C) VEGF-A expression in tumor tissues of mice treated 
with Bay60-6583 or vehicle (ctr), receiving the STAT3 inhibitor S3I-201 or 
vehicle. D) Tumor volume measured in mice treated as described above. Data are 
from three different experiments and represent mean ±SEM (n=6-10 per group). 
*p<0.05, **p<0.01, ***/ °°°p<0.001.  
 
 
2.3.5 Pharmacological blockade of A2BR reduces angiogenesis by preventing 
MDSCs accumulation 
Found out that A2BR stimulation promotes tumor growth and angiogenesis in 
melanoma-bearing hosts, we verified whether pharmacological inhibition of A2BR 
could have a therapeutic potential in reducing tumor angiogenesis. Melanoma-
bearing mice were treated with the selective A2BR antagonist PSB1115 (1 mg/kg, 
p.t.) every day for one week. Tumor growth was significantly reduced in 
PSB1115-treated mice (Figure 2.3.5 A). This effect was associated with reduced 
VEGF-A expression (Figure 2.3.5 B), and microvessel density (Figure 2.3.5 C). 
As we have previously demonstrated (39), A2BR blockade reduces tumor 
accumulation of MDSCs, preventing T-cells suppression in mice with melanoma 
(34). These results, together with those described above, support the critical role 
of MDSCs in contributing to the tumor-promoting activity of A2BR, including 
angiogenesis.  
Inasmuch as MDSCs accumulation is a resistance factor to anti-VEGF therapies 
(75, 76), we hypothesized that PSB1115, by reducing the accumulation of tumor-
infiltrating MDSCs, might potentiate the effects of anti-VEGF treatment when 
used in combination with it. PSB1115 alone reduced tumor growth (Figure 2.3.5 
A). Treatment of mice with anti-VEGF antibody delayed tumor growth compared 
to controls (Figure 2.3.5 D) and the combination of anti-VEGF treatment with 
PSB1115 inhibited tumor growth much better than anti-VEGF or PSB1115 alone 
(Figure 2.3.5 D). Moreover we verified that mice treated with both drugs showed 
reduced number of tumor-infiltrating MDSCs (Figure 2.3.5 E) and increased 
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Figure 2.3.5 A) Tumor volume of mice treated with PSB1115 or vehicle (ctr). B) 
VEGF-A expression in melanoma lysates harvested from mice treated with 
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immunofluorescence staining in melanoma sections of mice treated with PSB1115 
or vehicle (ctr). D) Measurement of tumor growth after PSB1115 or vehicle in 
combination with anti-VEGF antibody treatment. E) F) and G) Percentage of 
MDSCs and CD3+CD8+ cells or CD3+NK1.1+ cells, respectively. Data are from 
three different experiments and represent mean ±SEM (n=9-12 per group). 
*p<0.05, **p<0.01, ***p<0.001. 
 
To sum up, our data show that treatment of mice with A2BR antagonist was able to 
reduce tumor growth through the inhibition of both angiogenesis and 
immunosuppression. These effects are, at least in part, dependent on the activity 
of PSB1115 in reducing tumor-infiltrating MDSCs. The latter could also justify 
the enhanced effectiveness of VEGF-A inhibitor treatment.   
 
 
2.3.6 A2BR stimulation induces CXCL12 expression in FAP positive cells 
within melanoma tissues 
In an attempt to fully characterize the role of A2BR in the surrounding stroma, we 
then focused our attention also on the activity of stromal fibroblasts within tumor 
microenvironment upon A2BR stimulation or inhibition.  
Fibroblasts in tumor tissue express A2BR (Figure 2.3.6 A), in line with previous 
findings (50, 77). To verify whether A2BR stimulation could drive fibroblasts 
activation within melanoma tissues we examined in melanoma sections the 
expression of fibroblast activation protein (FAP). FAP is a common marker of 
activated fibroblasts also named cancer-associated fibroblasts (78, 79). The 
number of FAP positive cells in melanoma sections harvested from mice treated 
with Bay60-6583 resulted significantly increased compared with those observed 
in control mice (Figure 2.3.6 B). Tumor-associated fibroblasts are important 
players within tumor stroma, able to produce and secrete various tumor-promoting 
factors, including fibroblast growth factor (FGF)-2 and CXCL12 or stromal-
derived factor 1 α (SDF1α) (52, 80). We observed that both FGF-2 and CXCL12 
expression were higher in tissues harvested from mice treated with Bay60-6583 
than controls (Figure 2.3.6 C). FAP positive cells are one of the major source of 
these mediators under our experimental conditions (Figure 2.3.6 D), in line with 
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Figure 2.3.6 Immunofluorescence analysis of A) A2BR expression on FAP+ cells 
B) FAP+ cells and C) FGF-2+ cells in melanoma sections harvested from mice 
treated with Bay60-6583 or vehicle (ctr). D) Number of CXCL12+ cells, FGF2+ 
cells and FAP+ CXCL12+ cells in tumor tissues harvested from mice treated with 
Bay60-6583 or vehicle (ctr). Data represented are from three different 




2.3.7 A2BR stimulation induces FGF-2 and CXCL12 expression in isolated 
melanoma-associated fibroblasts 
We then isolated fibroblasts from melanoma tissue. Isolated cells treated with 10 
nM Bay60-6583 for 24 hours showed increased expression of both FGF2 and 
CXCL12 compared to vehicle-treated cells (Figure 2.3.7_1 A). These effects were 
reverted by treating melanoma-associated fibroblasts with the A2BR antagonist 
PSB1115 at 100 nM (Figure 2.3.7_1 B), demonstrating that the increased FGF-2 
and CXCL12 expression in melanoma-associated fibroblasts treated with Bay60-
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Figure 2.3.7_1 A) Representative immunofluorescence image of melanoma-
isolated fibroblasts from mice treated with Bay60-6583 or vehicle (ctr), stained 
with FGF-2 and CXCL12 antibodies. B) Analysis of CXCL12 and FGF2 
expression in melanoma-isolated fibroblasts stimulated or not with Bay60-6583 
10nM or PSB1115 100nM for 24 hours. 
 
Similar results were also obtained in fibroblasts isolated from skin of C57Bl6 
mice exposed for 24 hours to a hypoxia-inducing treatment (CoCl2 100 µM) as a 
tumor stressor (81) and then treated with Bay60-6583 for other 24 hours (Figure 
2.3.7_2 A). In these experimental conditions, the expression of HIF-1α was 
induced in hypoxic cells compared with control cells (Figure 2.3.7-2 D). 
Although, the expression of A2BR could be induced in a HIF-1α-dependent 
manner (50), we surprisingly observed that the A2BR expression was not induced 
in hypoxic fibroblasts (Figure 2.3.7_2 B), while CD73, the enzyme responsible 
for the production of extracellular adenosine, was induced (Figure 2.3.7_2 C).  
Since A2BR share with the A2AR many similarities, to verify whether A2BR was 
the only adenosine receptor involved in promoting fibroblasts activation in our 
melanoma model, we treated isolated fibroblasts with the selective A2AR agonist 
CGS21680 (1 µM) showing that A2AR stimulation did not have any effect on the 
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Figure 2.3.7_2 A) Immunofluorescence image of skin-derived fibroblasts 
exposed to hypoxia (100µM CoCl2) for 24 hours and then stimulated with Bay60-
6583 10nM for another 24 hours or control cells. Western blotting analysis of B) 
HIF1α and A2BR expression and C) CD73 expression in skin-derived fibroblasts 
under hypoxic conditions. D) Expression of CXCL12 and FGF2 upon A2BR 
(Bay60-6583) and A2AR (CGS21680) stimulation in isolated fibroblasts. Data 
represented are from three different experiments and represent mean ±SEM (n=10 
per group). *p<0.05, **p<0.01, ***p<0.001. 
 
Accordingly, our findings suggest a sole role of A2BR in fibroblast activation 
within tumor microenvironment, which helps to promote tumor growth. 
 
 
2.3.8 FGF-2 released from fibroblasts upon A2BR stimulation induces 
melanoma cells proliferation  
The proliferation of B16-F10 melanoma cells co-cultured with fibroblasts in vitro 
increased after administration of Bay60-6583 and it was blocked when the A2BR 
antagonist PSB1115 was added to the co-culture (Figure 2.3.9 A). Since 
stimulation of A2BR in fibroblasts induces FGF-2 expression we hypothesized that 
the increased proliferation of B16-F10 cells co-cultured with fibroblasts was due 
to fibroblast-derived FGF-2 upon Bay60-6583 administration. To test this 
hypothesis, we administered to cells an anti-FGF2 antibody (30-100 ng/ml) that 



























proliferation of neither isolated fibroblasts (Figure 2.3.9 B) nor B16.F10 
melanoma cells alone (data not showed) was affected by Bay60-6583 treatment.  
 
A)               B) 
 
         
 
Figure 2.3.9 A) Proliferation of B16-F10 melanoma cells co-cultured with tumor-
associated fibroblasts (ratio 1:1) in presence of vehicle (ctr), Bay60-6583, anti-
FGF2 antibody or both in combination for 24 hours. B) Proliferation of 
melanoma-associated fibroblasts. Data represented are from two different 
experiments and represent mean ±SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
Altogether, these findings suggest that FGF-2, released from fibroblasts upon 




2.3.9 A2BR-induced CXCL12 expression in stromal cells contributes to its 
pro-angiogenic effect 
Afterwards, we decided to investigate and study the involvement of 
CXCL12/CXCR4 pathway in our experimental conditions. CXCL12 and its 
receptor CXCR4 are important for immunosuppressive cells recruitment such as 
MDSCs and Tregs within tumor microenvironment (34) and for tumor 

























































pathway in A2BR-mediated effects within tumor environment, melanoma-bearing 
mice were treated with AMD3100, a selective CXCR4 receptor antagonist (86, 
87), which was able to partially block the pro-tumor activity of Bay60-6583 in 
vivo (Figure 2.3.10 A). AMD3100 treatment did not suppress either the 
accumulation of MDSCs or the percentage of tumor-infiltrating CD8+, CD4+ T 
cells or FoxP3+ T cells (Figure 2.3.10 B, C, D and E, respectively). Conversely, 
CXCR4 blockade was able to reduce the microvessel density induced by Bay60-
6583 (Figure 2.3.10 F). 
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Figure 2.3.10: A) Tumor growth measured in control mice (ctr) or mice treated 
with Bay60-6583, AMD3100, AMD3100+Bay60-6583. Data represented are 
























###, p<0.001 versus AMD3100 and °°°, p<0.001 versus AMD3100 + Bay60-6583 
(ANOVA). B), C), D) and E) Cytofluorimetric analysis of CD11b+Gr1+ cells, 
CD3+CD4+ T cells, CD3+CD8+ T cells and CD4+FoxP3+CD25+ cells, 
respectively, in melanoma tissues of mice treated as described. F) Number of 
CD31+ cells (upper) and immunofluorescence image showing CD31 and CXCR4 
expression (lower) in melanoma tissue sections of mice treated as described 
above. Data represented are from two different experiments and represent mean 
±SEM. *p<0.05, **p<0.01, ***p<0.001. 
	
Taken together, these data suggest that A2BR-induced CXCL12 expression in 
stromal cells contributes to its pro-angiogenic effect rather than immune-
suppressive effects, establishing a positive cross-talk between fibroblasts and 
endothelial cells that sustains tumor growth.  
	
	
2.3.10 A2BR inhibition reduces FAP and FGF-2 expression within melanoma 
tissues 
Our results indicate that A2BR may have an important role in enhancing the 
activation of stromal cells, that release tumor-promoting mediators. To prove the 
translational potential of these findings we verified whether the administration of 
A2BR antagonist PSB1115 in mice was able to affect the activity of melanoma-
associated fibroblasts in vivo. Melanoma sections from PSB1115-treated mice 
showed a reduced number of FAP+ cells (Figure 2.3.11 A) and these data were 
also confirmed by flow cytometric analysis (Figure 2.3.11 B).  
Since the number of FAP cells could be related to the tumor volume, and in 
PSB1115-treated mice the tumor volume results significantly lower than those 
observed in control mice, we performed these analyses in tumors of similar sizes 
harvested from either PSB1115-treated mice and control mice. The number of 
FAP+ cells did not correlate with the size of tumor (Figure 2.3.11 C) suggesting 
that the reduced number of these cells in PSB1115-treated mice is dependent on 
the treatment rather than reduced tumor size. Moreover, we also verified that 
melanoma sections of mice treated with PSB1115 also showed reduced 
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Figure 2.3.11 A) Representative immunofluorescence image (left panel) and 
number of FAP+cells (right panel) in melanoma tissues from PSB1115 treated 
mice and control mice (ctr). B) FAP positive cells in PSB1115 treated mice 
compared to control mice analysed by flow cytometry. C) Number of FAP+ cells 
in control mice and mice treated with PSB1115 in correlation with the tumor size. 
D) Number of SDF+ (or CXCL12+) cells (left panel) and FGF2+ SDF+ cells 
(right panel) in PSB1115-treated mice compared with control mice. Data 
represented are from two different experiments and represent mean ±SEM. 






Tumor microenvironment is made up of several different types of cells, including 
malignant cells, endothelial cells, cancer-associated fibroblasts and tumor-
infiltrating immune cells that cooperate to the development of cancer. Adenosine 
plays a pivotal role in tumor immunity, angiogenesis and metastasis, promoting 
the development of anti-cancer strategies to inhibit tumor adenosine production 
and functions (for example by using CD73 inhibitors or selective A2AR blockers 
alone or in combination with chemotherapeutic agents and immune-checkpoints 
inhibitors). Emerging evidence suggest that A2BR can mediate the pro-tumor 
effects of adenosine in the tumor microenvironment and targeting A2BR has 
proved to be effective in some murine tumor models but the mechanisms 
underlying these effects are still incomplete. 
Here we investigated the effects of pharmacological modulators of A2BR in tumor 
tissue and surrounding stroma. We firstly demonstrated that A2BR stimulation 
promotes tumor growth in vivo by inducing both tumor immunosuppression and 
angiogenesis. These effects were associated with an increased presence of 
MDSCs within tumor lesion, that can critically impair T cell proliferation and 
activity, as well as tumor angiogenesis.  
Anti-VEGF therapy can be effective in controlling tumor growth especially in 
human cancer patients (88-91) but the efficacy of these therapies can be limited 
by several mechanisms, including accumulation of MDSCs in tumor lesions (92). 
Melanoma-bearing mice treated with Bay60-6583, a selective ligand of A2BR, 
showed accumulation of CD11b+Gr1+ cells, reduced number of T cells and 
enhanced VEGF-A expression and vessel density within tumor tissue. Several cell 
types may contribute to A2B-induced VEGF-A secretion including endothelial 
cells, which express A2BR. Stimulation of both melanoma cells and isolated 
CD11b+ cells with Bay60-6583 did not induce VEGF-A secretion. However, the 
selective depletion of Gr1+CD11b+ cells in vivo reduced VEGF-A expression in 
tumor tissues, leading to a significant delay in the tumor progression. Therefore, 
MDSCs accumulation within tumor lesions induced by A2BR stimulation is 
responsible not only for MDSC-mediated immune suppression in the tumor 
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microenvironment but also for enhanced tumor angiogenesis. Furthermore, one of 
the main transcriptional activators of VEGF-A expression in tumor lesions is 
STAT3, whose activation upregulates the expression of inflammatory and pro-
angiogenic genes, including VEGF-A leading a strong tumor progression and 
angiogenesis (93). We observed that the activation of STAT3 enhanced in 
melanoma tissue of mice treated with Bay60-6583. Accordingly, inhibition of 
STAT3 abrogated the pro-tumor activity of Bay60-6583 and reduced tumor 
VEGF-A expression. Nevertheless, we still do not know if in our model, A2B 
stimulation can directly act through STAT3 considering that STAT3 can be also 
activated by other pro-angiogenic factors. Previously our group demonstrated that 
adenosine could increase the IL10 release (34) that could lead to STAT3 
activation in M2-like macrophages in an A2BR dependent manner (94). This 
hypothesis reserve more future investigations. 
Importantly, pharmacological blockade of A2BR with PSB1115 significantly 
reduced tumor growth. This effect is associated with reduced expression of 
VEGF-A and vessel density within melanoma sections and reduced the presence 
of MDSCs in the tumor, which critically contribute both to inhibit T cell response 
and release VEGF-A. Of note, the effectiveness of anti-VEGF treatment enhanced 
in mice treated with PSB1115. Therefore, targeting A2BR with a selective 
antagonist can limit tumor growth by reducing tumor angiogenesis and MDSC-
mediated immunosuppression.  
Tumor-associated fibroblasts are critical component of tumor stroma and they 
produce and secrete various tumor-promoting factors including CXCL12/SDF1α. 
We next demonstrated that A2BR stimulation resulted in enhanced number of FAP 
and FGF-2 positive cells in melanoma lesions and accordingly PSB1115-treated 
mice showed a reduced number of FAP and FGF-2 positive cells compared to 
controls. Stimulation of A2BR was also correlated to an increased CXCL12 
expression in FAP+ cells both in melanoma tissues and in isolated tumor-
associated fibroblasts. Similar results were obtained in isolated mouse skin 
fibroblasts exposed to CoCl2 to mimic hypoxic conditions, a common feature of 
tumor microenvironment. These effects were A2BR-dependent as demonstrated by 
the co-administration of A2BR antagonist PSB1115 and by data from cells treated 
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with the A2AR agonist CGS-21680, which did not affect either FGF-2 or CXCL12 
expression. We evaluated the expression of A2BR in the cell lysates and, in 
contrast to our expectation, we were unable to find any regulation of A2BR 
expression. Conversely, CD73 expression was up-regulated in hypoxic fibroblasts 
confirming that these cells can contribute to the production of extracellular 
adenosine. We also observed that FGF-2 stimulation directly promoted the 
proliferation of B16-F10 melanoma cells co-cultured with tumor-isolated 
fibroblasts. Altogether, these findings suggest that this growth factor, FGF-2, 
released from fibroblasts upon A2BR stimulation may participate to the pro-tumor 
effects of the A2BR by inducing melanoma cells proliferation. The next step was 
to investigate and study the involvement of CXCL12/CXCR4 pathway in our 
melanoma mouse model. In our melanoma mouse model, B16-F10 melanoma 
cells did not express CXCL12 or CXCR4. From the literature we know that the 
inhibition of CXCR4 with AMD3100 improves T-cell responses in pancreatic 
cancer or prevents immune suppression in UV-induced skin cancer (95-97). In our 
melanoma mouse model, AMD3100 did not suppress the accumulation of tumor 
MDSCs and did not change the number of FoxP3 regulatory T-cells or CD8+T 
cells infiltrated into the melanoma lesions of Bay60-6583-treated mice compared 
to control mice. Instead, CXCR4 blockade was able to reduce the microvessel 
density induced by Bay60-6583.  
To sum up, in this Chapter, we described a novel role for A2BR which consists in 
promoting tumor growth by 1. contributing to the adenosine–mediated 
immunosuppressive effects, by regulating the accumulation of MDSCs within 
tumor tissue (MDSCs are potent suppressors of T effector cells) that critically 
contribute also to the pro-angiogenic effects of A2BR within tumor 
microenvironment  and 2. modulating the activity of stromal fibroblasts that, in 
turn, produce tumor-promoting soluble factors such as FGF-2 and CXCL12. 
These results provide new insights into the mechanisms through which 
pharmacological manipulation of A2BR regulates intercellular crosstalk in the 
tumor microenvironment and support the therapeutic potential of A2B antagonists 



























CD8+ T cells are activated upon their TCR stimulation in response to 
cognate peptide MHC II complexes on antigen-presenting cells (APCs) and co-
stimulatory molecules, including CD80 and CD86 (Figure 3.1.1). The adenosine 
receptor mainly expressed on lymphoid cell population is A2AR, whose 
stimulation is able to interfere with the early events upon T cell receptor (TCR) 
activation determining T cell anergy, in a cAMP-dependent manner (17, 98-100).  
                   
  
 
                      Figure 3.1.1: Purinergic signalling in effector T cells (101). 
 
Adenosinergic modulators of A2AR suppress the activation and effector functions 
of T cells (17, 98, 102). In naive CD8+ T cells adenosine via A2AR inhibits early 
TCR signalling events by reducing ZAP 70 tyrosine phosphorylation, which is 
required for the TCR signal transduction (Figure 3.1.1). This effect is a 
consequence of reduced activity of the kinase Csk, whose phosphorylation is in 
Modified by Cekic et al.,Nature (2016) 
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turn inhibited by protein kinase A (PKA) type I (103). In other words, stimulation 
of A2AR in CD3/CD28 activated T cells, increasing cAMP levels, activates the 
PKA which inhibits proximal TCR signalling events, including the 
phosphorylation of ZAP 70, preventing the phorsphorylation of Akt and ERK1/2 
and the calcium influx (Figure 3.1.1) (104). 
 
T cells are essential effectors of tumor immunity (18). One of the crucial 
signalling pathway involved in T-cell development, lineage selection and 
activation is Notch. Recent studies highlight the pivotal role of Notch signalling in 
the differentiation and function of several T cell subsets (19). Notch proteins 
(Notch 1-4) are transmembrane receptors that are activated by engagement of 
transmembrane-bound ligands (Delta-like 1, 3, 4 and Jagged 1, 2, although Delta-
like 3 is likely an inhibitory receptor) (Figure 3.1.2). 
 
    
   Figure 3.1.2: Schematic diagram of receptors and Notch ligands (105). 
 
The interaction of Notch receptors with their ligands leads to a proteolytic 
cleavage that can release the active intracellular domain of Notch (NICD) 
(canonical Notch activation pathway). However Notch can be also activated upon 
TCR stimulation in a non-canonical fashion in the absence of Notch receptor 
ligation (20). NICD then translocates into the nucleus where it associates with the 
transcriptional repressor CSL (CBF1-Suppressor of Hairless-Lag1), recruiting a 
co-activator complex, resulting in the expression of genes regulated by CSL (103) 




          
 
Figure 3.1.3: Schematic diagram of Notch expression and activation (106). 
 
A number of pharmacological strategies have been developed to target Notch 
signalling pathway at different levels of the cascade, including monoclonal 
antibodies against receptors and ligands (107-109) and γ-secretase inhibitors 
(GSIs) that can prevent the last cleavage of Notch, decreasing the levels of NICD 
(110, 111). 
It is well documented that Notch signalling is required for T-cell activation and 
for the cytotoxic activity of CD8+ T cells (112). Notch1 is also required for the 
differentiation of CD8+ effector cells (21) and constitutive expression of active 
Notch1 renders CD8+ T cells resistant to the immune suppressive activity of 
MDSCs (22). 
 
Here we evaluated the possible Notch1-A2AR signalling pathways cross-talk in 





3.2 Materials and Methods 
 
3.2.1 Cell isolation 
Splenocytes were collected aseptically from the spleen of naïve C57Bl6 mice, 
NIIC mice and A2AKO (kindly provided by Dr. Sitkovsky) and CD8+ T cells were 
isolated by immunomagnetic negative selection kit (EasySep Mouse CD8+ T Cell 
Isolation Kit, Stem Cell Technologies). Briefly, harvested spleens were 
mechanically digested in sterile PBS (Phosphate-Buffered Saline) and splenocytes 
suspension was processed with the Isolation Kit, according to manufacturer's 
instruction, to isolate CD8+ T cell. Isolated cells were seeded on an anti-
CD3/CD28 antibodies-coated plate and cells were treated at time 0 or after 24 
hours from the activation with the following agents: 
- CGS-21680 1 µM, A2AR agonist (Tocris), 
- ZM-241385 1 µM, A2AR antagonist (Tocris), 
- PF-03084014 1 µM, Notch1 inhibitor (Selleckchem), 
- Forskolin 10 µM, adenylate cyclase stimulator (Sigma-Aldrich), 
- Cycloheximide 10 µM (Sigma-Aldrich). 
CD8+ T cells were grown in RPMI 1640 medium supplemented with 10% FBS, 4 
mM L-Glutamine, 50 U/mL penicillin, 50 µg/mL streptomycin and 50 µM 2-
mercaptoethanol. 
 
3.2.2 Proliferation assay 
To study how the treatments could affect CD8+ T cells proliferation, cells were 
stained with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE, Life 
technologies) according to manufacturer’s protocol. Stimulated cells were 
collected after 72 hours of treatments (treated at time 0 or after 24 hours from the 
activation) and analysed by flow cytometer. 
 
3.2.3 Enzyme-Linked Immunosorbent Assays 
Granzyme B and IFN-γ concentration was measured by ELISA kits (Invitrogen by 
Thermo Fisher Scientific) in the supernatants of CD8+ T cells after 72 hours of 
treatments (treated at time 0 or after 24 hours from the activation). 
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3.2.4 Western blotting 
Cells were collected and washed in PBS before RIPA buffer lysis (SantaCruz 
Technology) in which was freshly added 1mM Protease and Phosphatase Inhibitor 
Cocktail (Thermo Scientific), 1 mM PMSF and 1 mM sodium orthovanadate. 
After protein concentrations determination, using Bio-Rad protein assay, samples 
were analysed by 7.5% Criterion TGX Precast Gels (Bio-Rad) and transferred 
electrophoretically to PVDF membranes (Immobilion-FL Transfer Membrane) or 
nitrocellulose membranes. Bovine serum albumin (BSA, Sigma) was used to 
block non-specific binding sites and membranes were incubated then with 
primary antibodies to evaluate the expression of Cleaved Notch 1 (NICD), Notch1 
(C-20-R, sc-6014), pAKT (Ser473), Akt (pan), pGSK-3β (Ser9), GSK-3β (all 
these antibodies were purchased from Cell Signaling) and GAPDH, β-actin or β-
tubulin (Santa Cruz) as protein loading control. After incubation with secondary 
antibodies, immunoreactive protein bands were detected by enhanced 
chemiluminescence reagents (Amersham Pharmacia Biotech, Buckinghamshire, 
UK) and analysed by Las4000 (GE Healthcare Life Sciences). 
 
3.2.5 Real time RT-PCR  
mRNA levels from CD8+ T cells were analysed by Real-time PCR. Total RNA 
was isolated from treated cells using RNeasy Mini kit (Qiagen) following the 
manufacturer’s instructions. Reverse transcription was performed with random 
hexamer primers or specific primers using the First strand cDNA synthesis Kit 
(Fermentase Life Science Co., EU) according to the manual. cDNAs were 
amplified by real time PCR using iTaqTM SYBR Green Supermix with ROX 
(Bio-RAd, CA). Samples were run in triplicate in a 96well Optical Reaction plate 
(Applied Biosystems, CA). The PCR reaction conditions were: 50°C for 2 min, 
95°C for 5 min, 35 cycles of 95°C for 30 sec, 59°C for 1 min, 72°C for 1 min, 
followed by dissociation step. Results were analysed by utilizing the 7300 system 
Software (Applied Biosystems, CA).  












3.2.6 cAMP assay 
To study the involvement of cAMP pathway in Notch1-modulated signal upon 
A2AR stimulation, we performed a cAMP assay (abcam_ab65355) according to 
manufacturer's instruction. cAMP levels were measured in cells after 10 min of 
treatment with CGS-21680 1µM or Forskolin 10µM. The kit used was made up of 
recombinant Protein G coated 96-well plate to efficiently anchor cAMP 
polyclonal antibody on to the plate. cAMP-HRP conjugate directly competed with 
cAMP present in samples of activated CD8+ T cells and bound to the cAMP 
antibody on the plate. The amount of cAMP-HRP bound to the plate can easily be 
determined by reading HRP activity at OD 450 nm. The intensity of OD 450 nm 
is inversely proportional to the concentration of cAMP in samples. 
 
3.2.7 Statistical analysis 
Data are from at least two-three independent experiments and results are 
expressed as mean ± SEM.  
The optical density of the protein bands detected by Western blotting was 
performed with ImageQuantTL (Ge Healthcare). Data were analysed with 
GraphPad Prism 6 (GraphPad Software). Two-tailed Student’s t test (2-group 
comparisons) or ANOVA (> 2-group comparisons) were performed as 







3.3.1 A2AR stimulation leads to reduced expression of NICD and Notch1 in 
activated CD8+ T cells 
Although Notch1 expression and activation is known to be induced in a TCR-
dependent manner and its activity is associated with proliferation of T cells and 
cytokines production (112), the effect of adenosinergic modulators of A2AR on the 
expression and activity of Notch is not known. To this end we used CD8+ T cells 
isolated from spleen of C57Bl6 mice. Cells were activated with anti-CD3/CD28 
antibodies. Consistent with previous results (112), the expression of Notch1 
proteins (the intracellular Notch1 domain, NICD, and the transmembrane Notch 1 
portion, Notch1TM) was induced in activated CD8+ T cells compared with 
unstimulated cells (Figure 3.3.1 A). Interestingly, we found that the expression of 
Notch 1 proteins was present from 3 hours up to 72 h of TCR stimulation (3-6-24-
48 and 72h) (data not shown) (113). Shown are data at 72 h of treatment, but 
similar results were obtained at all time points. To determine whether activation 
of A2AR affected the TCR-induced Notch1 expression, CD8+ T cells were treated 
with the selective agonist of A2AR CGS-21680 (1µM) and activated with anti-
CD3/CD28 antibodies. These experiments revealed that stimulation of A2AR leads 
to reduced expression of TCR-induced expression of Notch1 proteins (Figure 
3.3.1 B, C, D, E). The TCR-induced Notch1 expression was inhibited in presence 
of the γ-secretase inhibitor PF-03084014 (Figure 3.3.1 B, C, D, E). Moreover, the 
expression of Notch1 proteins was strongly inhibited in presence of both CGS-
21680 and the γ-secretase inhibitor PF-03084014 (Figure 3.3.1 B, C, D, E). The 
effect of CGS-21680 on Notch1 proteins expression was abrogated in presence of 
the A2AR antagonist ZM-241385 (1µM) (Figure 3.3.1 D, E). Stimulation of A2B 
receptor with Bay 60-6583 (A2BR selective agonist) and/or its antagonist PSB-
1115 (A2BR selective antagonist) did not induce similar effects, ruling out any role 
of A2B receptor in modulating the activation of Notch1 in CD8+ T cells upon TCR 




   A) 
    
 
 
B)           C) 
 
      
      
 
   D) 
           




       E) 
   
 
      F) 
                   
 
Figure 3.3.1. A) Isolated and activated CD8+ T cells with anti CD3/CD28 
antibodies expressed Notch1 proteins upon TCR stimulation (72h). Control cells 
are indicated as NS. Shown are the Notch1 intracellular domain (NICD) and the 
transmembrane portion of Nocth1 (NotchTM). B) and C) CD8+ T cells treated 
with an A2AR agonist (CGS-21680, 1 µM for 72 hours) or γ-secretase inhibitor PF 
(PF-03084014, 1 µM) or in combination (CGS+PF) showed decreased expression 
of TCR-induced NICD D) and E) Expression of Notch1TM in CD8+ T cells 
treated with an A2AR agonist CGS (CGS-21680, 1 µM), CGS in combination with 
A2AR antagonist ZM (ZM-241385, 1 µM), γ-secretase inhibitor PF (PF-03084014, 
1 µM) or in combination (CGS+PF) for 72 hours, showed decreased expression of 
NICD. F) A2BR agonist treatment (Bay-606583, 1 µM for 72 hours) alone or in 
combination with its antagonist PSB-1115 (B+P) had no effects on Notch 
activation in CD8+ T cells. Data represent mean ± S.D. and are from three 




















These results indicate that stimulation of A2AR resulted in down-regulation of 
Notch1 proteins in TCR-stimulated CD8+ T cells.  
To further investigate the effect of the A2AR agonist on TCR-induced Notch 
signalling pathway, RT-PCR analyses were performed to analyse the expression 
of Notch1 and NICD-targeted genes Hes1 and Myc (109, 110). As shown in 
Figure 3.3.1 G, the relative transcript levels of Notch1 remained unchanged upon 
CGS-21680 administration at 24h, 48h and 72h in activated CD8+ T cells. 
Conversely, the mRNA levels of Notch1-targeted genes Hes1 and Myc (109, 110) 
were reduced in cells treated with CGS-21680, PF-03084014 or CGS+PF (Figures 
3.3.1 H and I, respectively).  
  G) Notch1        
   
   
  H) Hes1 
        
D) 




  I) Myc 
             
Figure 3.3.1 G) Notch1 H) Hes1 and I) Myc relative mRNA levels after 24, 48 
and 72 hours of treatment of CD8+ T cells with CGS-21680, PF-03084014 or the 
combination (CGS+PF) upon activation with anti-CD3/CD28 antibodies. Data 
represent mean ± S.D. and are from three different experiments. *p<0.5, 
**p<0.01; ***p<0.001. 
 
Altogether these results indicate that although the stimulation of A2AR in activated 
CD8+ T cells did not directly control the transcription levels of Notch1, it is able 
to interfere with Notch1-dependent signalling, inhibiting NICD-mediated activity.  
 
3.3.2 A2AR stimulation and Notch1 inhibition strongly reduce the 
proliferation and effector functions of activated CD8+ T cells 
To investigate further the effect of A2AR stimulation on CD8+ T cells we 
measured the proliferation of T cells and the cytokines production after treatment 
of cells with CGS-21680 and the γ-secretase inhibitor upon TCR stimulation with 
anti-CD3/CD28 antibodies. The percentage of proliferating CD8+ T cells was not 
significantly altered after 72h of activation and treatment with CGS-21680 or PF-
03084014 alone, at the concentrations used in this work (Figure 3.3.2 A). 
However proliferation of activated CD8+ T cells was significantly reduced after 
treatment with CGS-21680 in combination with PF-03084014 (Figure 3.3.2 A). 
The levels of Granzyme B (Figure 3.3.2 B) and IFN-γ (Figure 3.3.2 C), measured 
D) 




in the supernatant of cells, significantly reduced in activated CD8+ T cells treated 
with CGS-21680 or PF-03084014 alone and even more after CGS+PF 
administration for 72h. The effect of GCS-21680 on Granzyme B (Figure 3.3.2 B) 
and IFN-γ (Figure 3.3.2 C) was completely reverted in presence of the antagonist 
ZM-241385. The levels of IFN-γ were also detected via RT-PCR. The relative 
transcript levels of IFN-γ in activated CD8+ T cells were significantly reduced 
after CGS-21680 or PF-03084014, alone or in combination, after 24-48 and 72 
hours of treatment (Figure 3.3.2 C).  
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Figure 3.3.2 A) Stimulation of A2AR with CGS-21680 in combination with a GSI 
(PF-03084014, 1 µM) for 72h significantly decreased proliferation rate. B) 
Granzyme B and C) IFN-γ levels and D) IFN-γ transcript levels in CD8+ T cells 
treated as described above. Data represent mean ± S.E.M.. and are from three 
different experiments. *p<0.5; ***p<0.001. 
These data confirm that activation of A2A adenosine receptor or inhibition of 
Notch pathway significantly affect the proliferation and cytokines production of 
activated CD8+ T cells. Notably, these inhibitory effects were enhanced in cells 
treated with both agents. 
 
 
3.3.3 Adenylate cyclase stimulation mimics the effects of A2AR on Notch1 
expression in activated CD8+ T cells 
Given that stimulation of A2AR inhibits the CD8+ T cells function by impairing 
the expression and activity of Notch1, we next investigated further the mechanism 
through which A2AR modulates the Notch signalling pathway. It has previously 
reported that stimulation of A2AR induce cAMP levels in CD3/CD28-stimulated 
CD8+ T cells (98, 104). Consistently, we observed that CGS-21680 treatment of 
CD3/CD28 activated CD8+ T cells increased cAMP levels within few minutes 
(Figure 3.3.3 A). Using an activator of adenylate cyclase forskolin (10µM), which 
significantly increased the cAMP levels in activated CD8+ T cells (Figure 3.3.3 
B), we found that the expression of Notch1 proteins induced by TCR engagement 
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Figure 3.3.3 A) and B) cAMP levels in activated CD8+ T cells treated with CGS-
21680 (1µM) or not (Ctr) or forskolin 10 µM, respectively. C) Representative 
Western blotting and D) and E) densitometric analysis of NICD and Notch 1 
expression, respectively, in unstimulated (NS) and activated (Ctr) CD8+ T cells 
treated with Forskolin alone or in combination with PF-03084014. Data represent 
mean ± S.E.M. and are from three different experiments. *p<0.5; **p<0.01; 
***p<0.001. 
 
These results indicate that the increased levels of cAMP within activated CD8+ T 
cells after A2AR stimulation can inhibit the TCR-induced Notch 
expression/activation. 
Forskolin was able to affect CD8+ T cells functions as shown in Figures 3.3.3 F, 
G and H. In particular, Forskolin (10µM) significantly reduced the percentage of 
proliferating CD8+ T cells after activation and this effect was enhanced in 
presence of PF-03084014 (Figure 3.3.3 F). Moreover, forskolin significantly 
reduced IFN-γ (Figure 3.3.3 G) and Granzyme B (Figure 3.3.3 H), released by 
activated CD8+ T cells. 
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Figure 3.3.3 F) Stimulation of adenylate cyclase with forskolin in combination 
with PF-03084014 for 72h significantly decreased the proliferation rate of TCR-
activated CD8+ T cells. G) IFN-γ and H) Granzyme B production in CD8+ T 
cells treated as described above. Data represent mean ± S.E.M.. and are from three 
different experiments. *p<0.5, **p<0.01; ***p<0.001. 
 
These results suggest that the expression of Notch1 in activated CD8+ T cells can 
be significantly reduced by cAMP-elevating agents. 
 
 
3.3.4 A2AR stimulation after TCR activation does not affect CD8+ T cells 
functions 
A2AR stimulation by increasing the levels of cAMP inhibits TCR signalling early 
events during activation (111), by reducing the Zap70 phosphorylation which is 
the first event within TCR signal transduction (104). Therefore it is likely that 
stimulation of A2AR suppresses CD8+ T cells activation by inhibiting the TCR 
transduction and thus the TCR-dependent Notch induction. To test this, we treated 
cells with CGS-21680 24h later TCR stimulation with CD3/CD28 antibodies and 
evaluated the expression of Notch1 proteins. Notably, treatment of cells with 
CGS-21680 did not affect the expression of Notch1 proteins induced by TCR 
stimulation (Figure 3.3.4 A, B, C) or treatment of cells with the γ-secretase 
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Figure 3.3.4 A) Representative Western blotting of Notch 1TM and NICD in 
activated CD8+ T cells treated with CGS, PF and ZM 24h later TCR stimulation. 
B) and C) densitometric analysis of Notch 1 and NICD expression, respectively, 
in CD8+ T cells Treated as described above. 
 
We also observed that CGS-21680 lost its inhibitory effects on proliferation or 
cytokines release even in combination with PF-03084014 when administered to 
cells once the TCR stimulation has occurred (Figure 3.3.4 E, F and G). 
Conversely, the inhibitor of Notch1 significantly reduced the release of IFN-γ and 
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Figure 3.3.4 E) Proliferation rate of isolated and activated CD8+ T cells treated 
as described above, F) IFN-γ production G) Granzyme B production. Data 
represent mean ± S.E.M.. and are from three different experiments. *p<0.5, 
**p<0.01. 
 
Therefore, the results indicate that the suppressive effects of CGS-21680 through 
A2AR rely in its capacity to early block the TCR signalling, critical for Notch 
activation and they are lost once the TCR signalling transduction and thus NICD 
generation has occurred. 
 
3.2.5 CGS-21680 does not affect NICD stability 
It has revealed that adenosine, inhibiting the proximal TCR early events in T cells 
during activation, could also affect the downstream signalling molecules Akt 











































































































































































synthase kinase 3 (GSK-3) which is inhibited upon phosphorylation (114). 
Glycogen synthase kinase 3 (GSK-3) is implicated in many processes including 
regulation of protein stability (115). Both GSK-3α and GSK-3β forms regulate the 
proteasomal degradation of NICD/Notch 1 (116). In our conditions, we observed 
that CGS-21680 did not significantly reduced AKT phosphorylation (Figures 
3.3.5 A and B), and this effect was associated with unchanged levels of pGSK3β 
(Ser9) expression (Figures 3.3.5 C and D). It is important to note that 
independently of Akt status, GSK3 could be directly phosphotylated by PKA, 
induced by cAMP elevating agents (117). Therefore it is possible that stimulation 
of A2AR, that increases cAMP levels, although slightly reduced pAkt expression, 
could also on the other hand induce GSK3 phosphorylation/inactivation. 
Nonetheless, the levels of pGSK3 were unchanged in our experimental 
conditions. 
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Figure 3.3.5 A) Representative Western blotting and B) densitometric analysis on 
pAKT and total AKT expression in unstimulated (NS) and activated (Act) CD8+ 
T cells treated with CGS-21680 and ZM-241385. C) Representative Western 
blotting and D) densitometric analysis on pGSK3β and total GSK3β expression in 
CD8+ T cells treated as described above. Data represent mean ± S.E.M. and are 
from three different experiments. 
 
To confirm that CGS-21680 did not interfere with NICD stability, we treated 
isolated and activated CD8+ T cells in presence of the inhibitor of protein 
synthesis cycloheximide 10 µM (CHX) alone and in combination with CGS-
21680. We observed that CHX reduced NICD expression after 24 hours and this 
effect was similar to that observed in cells treated with CGS-21680 in 
combination (Figure 3.3.5 E) ruling out a possible effect of A2AR agonist on 
NICD stability.  
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Figure 3.3.5 E) Representative Western blotting of NICD and Notch1TM 
expression in isolated and activated CD8+ T cells treated for 24 hours with 
cycloheximide 10 µM (CHX) alone and in combination with CGS-21680. 
 
These results demonstrate that CGS-21680 inhibits the TCR-induced Notch1 








3.3.6 Ectopic expression of N1IC renders CD8+ T cells less susceptible to the 
suppressive effects of CGS-21680 
To determine whether the constitutive activation of Notch1 in CD8+ T cells could 
affect the suppressive activity of CGS-21680, we used transgenic CD8+ T cells 
expressing Notch1 (from N1IC mice) under the Granzyme B promoter compared 
with N1ICf/f cells (22). The expression of Notch1 in these cells occurred 24h later 
TCR stimulation (data not shown) (22). Therefore, both N1ICf/f and N1IC CD8+ 
T cells were treated with CGS-21680 or PF-03084014 24h after TCR activation, 
when the N1IC was over-expressed. Although, treatment of cells with CGS-21680 
or with the Notch1 inhibitor PF-03084014 alone after 24h of activation did not 
influence the proliferation of either N1ICf/f and N1IC CD8+ T cells (Figure 3.3.6 
A), co-treatment of cells with both CGS-21680 and PF-03084014 significantly 
reduced the proliferation of N1ICf/f cells but not those of N1IC CD8+ T cells 
(Figure 3.3.6 A). Treatment of activated CD8+ T cells over-expressing N1IC with 
CGS-21680 did not affect the percentage of CD8+IFNγ+T cells (Figure 3.3.6 B) 
or the expression of Granzyme B (Figure 3.3.6 C). In presence of the Notch1 
inhibitor PF-03084014, CGS-21680 was able to reduce the percentage of 
CD8+IFNγ+T cells (Figure 3.3.6 B) and the expression of Granzyme B (Figure 













































































 B)          
      
 C) 
 
Figure 3.3.6 A) Proliferation rate of isolated and activated CD8+ T cells from 
spleens of mice overexpressing Notch1 (N1IC CD8+ T cells), treated for 72 hours 
compared to N1ICf/f cells B) percentage of CD8+IFN-γ+ cells and C) 
representative Western blot showing Granzyme B expression in cells treated as 
described above. Data represent mean ± S.E.M.. and are from three different 
experiments. *p<0.5, **p<0.01; ***p<0.001. 
 
These results indicate that N1IC CD8+ T cells are less susceptible to the 
suppressive effects of CGS-21680, confirming that the A2AR suppressive activity 
through CGS-21680 is, at least in part, dependent on Notch1 inhibition. 
 
 
3.3.7 A2AKO CD8+ T cells are susceptible to Notch1 inhibition  
We finally performed experiments in CD8+ T cells of spleens harvested from 
mice lacking A2AR (A2AKO mice). As expected, CGS-21680 did not modulate the 






























antibodies (Figure 3.3.7 A), or the release of IFN-γ and Granzyme B (Figure 3.3.7 
B and C, respectively). Conversely, the experiments revealed that treatment of 
cells with the γ-secretase inhibitor PF-03084014 (1 µM) inhibits the TCR-induced 
expression of Notch1 in A2AKO CD8+ T cells (Figure 3.3.7 A). This effect was 
associated, accordingly, with reduced production of IFN-γ and Granzyme B 
(Figure 3.3.7 B and C, respectively) suggesting that the inhibition of Notch1 
signalling through GSI treatment kept working in a system without A2ARs. In fact, 
Notch1 expression was inhibited in GSI treated cells and not in A2AR agonist-
treated cells (Figure 3.3.7 A). In the same way, concerning CD8+ T cells 
functions, IFN-γ and Granzyme B production was reduced in GSI-treated cells but 
not in A2AR agonist-treated cells (Figure 3.3.7 B and C, respectively), indicating 
that in cells deficient of A2AR the inhibitory effects of the Nocth1 inhibitor occurs.  
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Figure 3.3.7 A) Notch1TM expression in isolated and activated CD8+ T cells 
from spleens harvested from A2AKO mice, treated for 72 hours with the A2AR 
agonist (CGS-21680, 1 µM) or with the γ -secretase inhibitor PF-03084014 (1 
µM) or both  (A), IFN-γ production (B) and (C) Granzyme B production detected 
in the supernatant of cells treated for 72 hours as described above . Data represent 
mean ± S.E.M. and are from three different experiments. **p<0.01; ***p<0.001. 
 
These results demonstrate that the effects of CGS-21680 on TCR-induced Notch1 
expression are dependent on A2AR stimulation. Indeed, in CD8+ T cells lacking 
A2AR the TCR-mediated Notch1 expression was not affected by CGS-21680, nor 
the cytokines production; whilst inhibition of Notch1 was associated with 






In this study we investigated the possible mechanisms of adenosine-Notch1 
crosstalk pathway in regulating CD8+ T cells activation and functions. It is well 
documented that adenosine is an “immune checkpoint inhibitor” that potently 
suppresses the activation and cytokines production in T cells in a cAMP/ PKA-
dependent manner (the predominant A2AR signalling pathway). A large number of 
studies demonstrate that blockade of this receptor or inhibition of CD73, which is 
responsible of the adenosine generation, can potently improve immune responses, 
especially in the context of cancer (118). Adenosine and adenosinergic 
modulators of A2AR prevent the activation of CD8+ T cells inhibiting the 
membrane-proximal signalling of TCR upon anti-CD3/CD28 treatment (104). 
These effects are dependent on A2AR-induced cAMP/PKA pathway, which 
inhibits the kinases involved in the phosphorylation of Zap70, that is an early 
event within TCR signalling transduction. Here, we report data on a novel 
mechanism by which A2AR signals in CD8+ T cells. A2AR agonist controls CD8+ 
T cells responses, preventing the TCR-mediated induction of Notch1. Notch1 
signalling is crucial for T cells development and it is required for optimal 
proliferation and cytokines production of peripheral T cells (112). Notch 
signalling deregulation can lead to T cell acute lymphoblastic leukemia (T-ALL) 
(119, 120).  
Notch receptor is activated upon ligation with Notch ligands, undergoing at least 
three critical proteolytic steps. The intracellular Notch domain (NICD), generated 
by γ-secretase complex during last proteolytic step, translocates into the nucleus 
and activates the Notch target genes, including Hes and cMyc (121). Alternatively, 
Notch receptor can be activated without Notch ligands interaction, in a non-
canonical way through TCR signals (122). The TCR-induced Notch activation is 
crucial for T cells functions. Indeed, Notch activity mediates the cytotoxic T cells 
activity through direct regulation of EOMES, perforin and Granzyme B 
expression (113). The exact mode of Notch1 activation induced by TCR 
signalling in CD8+ T cells has not been fully characterized. Nonetheless, very 
recently, it has been demonstrated a mode of TCR-mediated mechanism of Notch 
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activation and signalling in mature CD4+ T cells (123). As occurred in CD8+ T 
cells, stimulation of TCR signalling in CD4+ T cells induce Notch processing 
independently of Notch ligands, generating in turn the intracellular domain of 
Notch (123). In CD4+ T cells signals from TCR, including Lck, PLC and PI3K 
that trigger PKC activation, rapidly activate the Notch cleavage and induce 
endocytosis of the Notch receptor (123).  
We observed that in naïve CD8+ T cells stimulation of TCR with anti-CD3/CD28 
antibodies induce a rapid expression and activation of Notch1 which persist up to 
72h later TCR engagement. Interestingly we found that stimulation of A2AR upon 
TCR activation significantly reduced the Notch proteins expression and its 
activity. Indeed, the transcription of Hes1 and cMyc, that are direct targets of 
Notch-mediated transcription (121), were significantly reduced upon A2AR 
stimulation. In contrast, the transcription levels of Notch1 remained unchanged. 
These results strongly indicate that signals through A2AR prevent the TCR- 
induced Notch processing and thus its activity rather than direct control of its 
transcription. In support, the inhibitory effects of A2AR agonist on Notch1 
expression were lost once TCR signalling transduction has occurred. These results 
led us to suggest that stimulation of A2AR, which significantly increases cAMP 
levels, by blocking the early events of TCR signal transduction (98, 104), can led 
to downregulation of Notch because of impaired TCR-induced processing. We 
confirmed that the A2AR-induced downregulation of Notch was dependent on 
cAMP/PKA pathway because experiments performed with the adenylate cyclase 
activator forskolin induced effects in activated CD8+ T cells similar to those 
obtained with the A2AR agonist. It could be also possible that stimulation of A2AR 
leads to downregulation of Notch expression/activity by modulating NICD 
stability. GSK-3 phosphorylation can decrease Notch1 proteins expression and 
reduce Notch transcriptional activity (116). Our experiments revealed that the 
phosphorylation levels of GSK-3 remained unchanged upon A2AR stimulation in 
activated CD8+ T cells, ruling out the possibility that signals via A2AR may 
regulate NICD protein degradation. Furthermore, GSK-3 phosphorylation/activity 
is regulated by PKB/Akt. However, although in our experiments A2AR agonist 
slightly reduced the levels of pAkt, it is not surprising that the levels of pGSK-3 
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remained unchanged since the activity of GSK-3 can be also controlled by PKA 
(124).  
Other post-translational modifications of NICD upon A2AR stimulation, including 
membrane trafficking, may also occur. However, this possibility reserves more 
investigations. 
To evaluate the functional consequence of the effects of A2AR agonist on TCR-
mediated Notch signalling, we determined the proliferation and cytokines 
production of activated CD8+ T cells treated with CGS-21680 with or without a 
γ-secretase inhibitor PF-03084014. γ-secretase complex is required for activation 
of Notch receptor and inhibitors of this enzyme have been largely used to 
investigate the downstream targets of the Notch signalling pathway. Despite the γ-
secretase inhibitors are not selective for Notch1, because they target all four 
Notch receptors, we observed that in activated CD8+ T cells the expression and 
activity of Notch1 induced by TCR engagement were inhibited. These effects 
were associated with a strongly impairment of cytokines production confirming 
the important role of Notch for optimal function of mature T cells. The inhibitory 
effects of GSI on cytokines production occurred in TCR-activated CD8+ T cells 
even when the TCR signal transduction has already occurred (24 hours later). It is 
likely that, although Notch activation occurs within few hours following TCR 
stimulation, we have observed that expression and activity of Notch persist up to 
72 hours later TCR stimulation when thus the GSI did not influence anymore the 
appearance of NICD (that is already happened), but it can still blockade Notch 
activity in controlling the release of the cytokines IFN-γ and Granzyme B. In 
support, previous data indicate that the GSI can abrogates the NICD binding as 
well as the recruitment of NF-kB, which directly regulates IFN-γ, to the perforin 
and Granzyme B promoters (112, 113).  
The inhibitory effects of A2AR agonist were enhanced in presence of the Notch 
inhibitor. Proliferation of CD8+ T cells, which was strongly inhibited in cells 
treated with both agents, A2AR agonist and γ-secretase inhibitor, upon TCR 
stimulation, was not affected in cells 24 hours later TCR activation. These results 
led us to suppose that since the inhibitory effects of A2AR agonist are lost once 
TCR transduction has occurred, we observed a significant reduction of T cells 
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proliferation only when the inhibition of Notch expression and activity, by GSI is 
combined with the A2AR agonist, which contributes, at least in part, to inhibit the 
TCR-induced Notch processing. 
The inhibitory effects of A2AR agonist are lost in N1IC CD8+ T cells; in contrast 
the effects of Notch inhibitor occur in A2AKO CD8+ T cells. Indeed, the 
constitutive activation of Notch1 in CD8+ T cells, isolated from transgenic CD8+ 
T cells expressing Notch1 under the Granzyme B promoter (after 24h upon TCR 
activation), affect the suppressive activity of A2AR stimulation compared with 
N1ICf/f CD8+ T cells. As expected, Notch1 inhibitor blocked the cytokines 
release in N1ICf/f CD8+ T cells, while N1IC CD8+ T cells were completely 
resistant. Importantly, combination of Noch1 inhibition and A2AR stimulation 
induced a significantly inhibitory effect on effector functions of N1ICf/f cells, 
which was reversed after combination with the A2AR antagonist, but not in N1IC 
CD8+ T cells. This suggests that expression of N1IC renders CD8+ T cells 
resistant to the inhibitory effect of the combination of Noch1 inhibition and A2AR 
stimulation. In other words, CD8+ T cells overexpressing N1IC are less 
susceptible to the inhibitory effects of A2AR stimulation compared with N1ICf/f 
cells.  
Results in A2AKO cells confirm the critical role of A2AR in reducing activation 
and function of CD8+ T cells. Its inhibitory effects are at least in part dependent 
on blocking of Notch1 expression and activity induced by TCR engagement. On 
the other hands, these results also confirm the crucial role of Notch1 in controlling 
the functions of CD8+ T cells, including those lacking A2AR. 
In summary, these data, reveal a novel role for A2AR in regulating T cells effector 
responses. Stimulation of A2AR leads to downregulation of Notch proteins 
expression and activity, that is pivotal for optimal functions of mature T cells. 
Signal through A2AR inhibits the early events of TCR transduction, that trigger 
Notch receptor proteolytic processing. Understanding the mechanism of cross-talk 
between these pathways, adenosine and Notch, that are both crucial for 
proliferation and function of T cells, may help to guide the development of 
























CD73 as a potential marker of response prediction to anti-PD1 




Nowadays, adenosinergic system plays a pivotal role as an anti-tumor therapeutic 
potential target including A2AR or A2BR antagonists and CD39 or CD73 
inhibitors. Inhibition of CD73 or A2A/A2B blockade is able to significantly reduce 
tumor progression and metastasis in several tumor models, included melanoma 
(125). New associations and consortia are committed to develop new A2AR 
antagonists or human monoclonal antibodies against CD73, some of which are 
already in clinical trials in patients with malignancies (NCT02503774, 
NCT02655822, NCT02403193, NCT02740985). As widely described in Chapter 
1, CD73 (or ecto-5’-nucleotidase) is an ecto-enzyme which hydrolyses the 
extracellular AMP into adenosine, a potent anti-inflammatory mediator that 
critically impairs the anti-tumor immune response (1, 125). Importantly, recent 
evidence suggest that CD73 exists in two different forms. There are both an 
enzymatic form which is bounded to the membrane of many cell types (including 
immune cells, endothelial cells and tumor cells) and a soluble one (sCD73) in the 
serum whose levels are significantly increased in cancer patients compared with 
healthy individuals (126, 127), as well as in patients with acute inflammatory 
pancreatitis (128). CD73 is over-expressed and up-regulated in different types of 
human solid tumors (24) and in general CD73 over-expression is associated to a 
poor overall survival (OS) or progression-free survival (PFS) (129). Notably, very 
recently it has been demonstrated that patients who exhibited high tumor CD73 
expression developed acquired resistance to immunotherapy (12). In this context, 
identification and stratification of patients who will benefit from current and new 
immunotherapies, including anti-CD73 agents, alone or in combination regimen, 
would be useful. In the last part of this thesis, we proposed to measure soluble 
CD73 levels in the peripheral blood of patients with advanced melanoma 
receiving nivolumab as potential biomarker of response to immunotherapy. These 
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evidence could be very helpful to select patients to an appropriate therapy and 
then, neutralizing CD73 with clinically validated CD73 monoclonal antibodies 
could represent a highly potent and innovative therapy to enhance or overcome 
resistance to immunotherapy. 
 
4.1.1 Metastatic melanoma treatments 
Metastatic melanoma (MM) is the most aggressive tumor characterized by a very 
high rate of relapse and metastasis (130). Over the past years’ treatment of 
metastatic melanoma has been revolutionized with immunotherapy, also including 
inhibitors of modulatory receptors on T cells (also known as “immune 
checkpoints”), which can significantly improve T-cell mediated immune response 
against tumor cells (131). An antibody anti-Cytotoxic T Lymphocyte Antigen-4 
(CTLA-4) (ipilimumab, a co-inhibitory receptor expressed on the surface of T-
cells) was the first immune checkpoint blocker approved by US Food and Drug 
Administration (FDA) for metastatic melanoma patients (132). This agent can 
enhance T-cell proliferation and activation (133) and limit Tregs activity (134) by 
inducing a long-term regression of melanoma. Unfortunately, the therapeutic 
benefit of ipilimumab is limited to a small subset of patients (135-137) due to a 
severe immune-related adverse events and morbidity or even mortality (138-141). 
Later on other immune checkpoint molecules have been discovered among which 
we can find antibodies against programmed cell death protein-1 (PD-1, 
nivolumab, pembrolizumab and atezolizumab). In particular, nivolumab is a 
monoclonal antibody IgG4, completely human, which acts by blocking PD-1 
protein. PD-1 is a receptor expressed on both CD4+ T cells and CD8+ T cells that 
binds its ligands: PD-L1 expressed on different cell types including tumor cells, or 
PD-L2 on macrophages and dendritic cells, inhibiting the function of T cells 
(142). The concurrent blockade of different immune checkpoints might increase 
the success of immunotherapy in cancer patients (131). In fact, melanoma patients 
treatment with nivolumab alone or in combination with ipilimumab induce an 
objective response rate (44%-58%) higher that ipilimumab alone and a longer 
progression-free survival (143-145). Moreover, combining two different immune-
check point blockers results in a lower number of adverse events (146).  
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Initially, the expression of PD-L1 on melanoma cells was supposed to guide to the 
success of nivolumab treatment but other studies have showed that patients with 
PD-L1 negative tumors can also respond to nivolumab treatment (146-148). These 
reasons highlight the importance to find new biomarkers that better correlate with 






4.2 Materials and Methods 
 
4.2.1 Patients  
For this retrospective single-center study was used a total of 37 patients (male, 
n=21; female n=16) aged >18 years with metastatic stage IV melanoma and 
samples collected between January 1st 2015 and December 31st 2016 at the 
Department of Melanoma, Cancer Immunotherapy and Innovative Therapies Unit. 
N=13 patients of 37 patients (35%) had BRAF V600-mutant melanoma, n=19 
patients (51%) were wild-type for BRAF, while n=5 patients included in this 
study had unknown BRAF status. 27/37 patients (73%) did not have brain 
metastases, while n=7 patients (19%) had brain metastases. N= 24 patients (65%) 
had M1c disease and n=19 (51%) had an elevated lactate dehydrogenase level 
(LDH>480 International Units [IU]/liter).  
Patients treatment: patients who had previously received ipilimumab alone or in 
combination with a BRAF inhibitor (n=7 patients), received nivolumab (3mg/kg) 
every two weeks until disease progression or unacceptable toxicity appeared. The 
first patient’s tumor response check was after 12 weeks and then every 12 weeks 
until progression or the discontinuation of treatment according to the Response 
Evaluation Criteria In Solid Tumors (RECIST). 
The overall response rate (ORR) to nivolumab was 24% (9/37: 0 patients with 
complete response [CR] and 9 patients with partial response [PR]). The disease 
control rate (DCR) to nivolumab was 46% (17/37: 0 patients CR, 9 PR and 8 with 
stable disease [SD]). 46% of patients (17/37) showed progressive disease (PD); 
while 3 patients died before the assessment of response to treatment. 
 
4.2.2 CD73 enzyme activity 
To evaluate the CD73 enzyme activity of hydrolysing AMP to adenosine and 
inorganic phosphate, the concentrations of inorganic phosphate (Pi) was 
determined in serum with the Malachite Green assay kit (CliniSciences, Italy). 
CD73 enzyme activity was measured in patients serum obtained from blood 
sample of each patients withdrawn before starting nivolumab treatment. Briefly, 
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serum samples (100µg of proteins) were incubated in assay medium containing 
MgCl2 (10 Mm), NaCl (120 mM), KCl (5 mM), glucose (60 mM), Tris-HCl 
(50mM), pH 7.4 for 10 min. AMP (2 mM) was added as substrate and samples 
kept at 37°C for 40 min. To stop the reaction trichloroacetic acid (TCA, final 
concentration 5% w/v) was added. TCA also contributed to proteins precipitation 
allowing the measurement of inorganic phosphate (Pi) released during the 
hydrolysis of AMP using the Malachite Green assay according to the 
manufacturer’s instructions. To have the real value of Pi produced following 
enzymatic reaction, aspecific Pi released in absence of AMP in each sample was 
subtracted from the value obtained following incubation with AMP. To determine 
specificity, experiments were also performed in the presence of the CD73 
inhibitor, adenosine 5’-(a, b-methylene) diphosphate (APCP; Tocris Bioscience, 
Bristol, U.K.) (40-100 µM), which is a non-hydrolysable ADP analogue. For 
these experiments, samples were incubated with APCP in assay medium for 30 
min at 37°C before adding AMP. All samples were run in triplicate; results were 
expressed as Pi released (pmol/min/mg protein). All reagents, as not indicated 
otherwise, were from Sigma-Aldrich S.r.l. (Milan, Italy). 
 
4.2.3 Statistical analysis 
Differences in sCD73 enzyme activity values across patients’ characteristics were 
evaluated with the Mann-Whitney non parametric test. Chi-square test was used 
to study associations among categorical variables. Survival curves were estimated 
with the Kaplan-Meier method and differences evaluated with the log-rank test. 
Associations between CD73 values and survival times were measured with the 
Harrel’c. Best cut-off values were located with an R routine implemented on the 
online software (Cut-off Finder) which maximize differences in survival between 
the two groups. Hazard Ratios (HR) and their 95% confidence intervals (95% CI) 
were calculated using the proportional hazard model. Multivariate analysis was 






4.3.1 sCD73 enzymatic activity in patients with stage IV metastatic 
melanoma 
We started this retrospective study by analysing the basal levels of soluble CD73 
(sCD73) enzyme activity in the serum samples of patients with stage IV 
metastatic melanoma, before starting nivolumab treatment. 70% of the patients 
presented detectable CD73 enzyme activity. Importantly, in relationship to 
gender, age, BRAF status (wild-type versus mutated), brain metastases, LDH 
levels and number of previous therapy line, as summarized in Table 1, elevated 
sCD73 activity was significantly associated with male gender (P=0.007), but not 
with other variables (Table 1). Indeed, patients with BRAF V600-mutant 
melanoma had values of sCD73 enzyme activity similar to those measured in 
BRAF wild-type melanoma (P=0.99) (Table 1). No significant differences in the 
activity of sCD73 was found between patients with or without brain metastases 
(P=0.84), in patients with normal LDH versus patients with elevated LDH values 
(P=0.11), or in relationship to the number of previous line of treatment (P=0.28) 

















Table 1. sCD73 activity in metastatic melanoma patients 
 
 
*Mann-Whitney U test. WT: wild-type; mets: metastasis; LDH=lactate 
dehydrogenase; IU/L: International Units per Liter; N: Number. 
 
 
Samples with highest sCD73 enzyme activity were incubated with the non-
hydrolysable inhibitor of CD73, APCP (40-100µM) before adding the substrate 
AMP, to determine the specificity of the reaction. APCP significantly reduced the 
accumulation of Pi in a concentration-dependent manner [from 87.337 ± 27.995 
pmol/min/mg protein to 55.00 ± 38.658 pmol/min/mg protein (APCP, 40µM) and 
to 1.375 ± 2.428 pmol/min/mg protein (APCP, 100µM); n=4, P<0.05 Mann-









































































        	
Figure 1: APCP treatment (40-100µM) was able to reduce the activity of CD73. 
Data are mean ± SEM.	
 
4.3.2 Correlation among sCD73 enzymatic activity and survival 
To investigate association between sCD73 enzymatic activity values, overall 
survival and progression-free survival we calculated the Harrel’s C index. We 
found a good association of c=0.68 (0.45-0.92) for overall survival and c=0.65 
(0.44-0.85) for progression-free survival. 
Moreover we calculated the optimal cut-off value to establish the sensitivity and 
specificity of sCD73 enzyme activity thresholds for survival. The optimal cut-off 
of sCD73 activity for both overall survival and progression-free survival was 
27.82 pmol/min/mg protein, as determined by Cut-off Finder online software 
(Figure 2). Among patients with metastatic melanoma analysed in this study, 
27/37 (73%) patients showed a cut-off value of sCD73<27.8 pmol/min/mg protein 
and 10/37 (27%) patients with sCD73>27.8 pmol/min/mg protein. Median overall 
survival was not reached in patients with low values of sCD73 enzyme activity 
(<27.82 pmol/min/mg protein) compared with 6.1 (95%Confidence Interval [CI]: 
0-14.8) months for patients with elevated sCD73 enzyme activity (>27.82 
pmol/min/mg protein) (Figure 2A; P<0.0001), when patients were follow-up for a 
median of 24 months. Median progression-free survival was 14.2 months (95% 
CI: 4.6-23.8) in patients with low sCD73 enzyme activity (<27.82 pmol/min/mg 
protein) and 2.6 months (95% CI: 1.9-3.3) in patients with sCD73enzyme activity 
































            
 
Figure 2: Kaplan Meyer curves for A) overall survival and B) progression-free 
survival. 
 
4.3.3 sCD73 enzyme activity as possible prognostic factor in metastatic 
melanoma 
To evaluate the impact of gender, age, BRAF status, LDH levels, line of 
treatment, brain metastasis or basal activity of sCD73 on response to nivolumab, 
univariate logistic regression was performed. Serum lactate dehydrogenase (LDH) 
is one of the most important recognized independent prognostic factor in 
melanoma patients with stage IV disease (113). Elevated LDH levels were found 
to be significantly associated with worse overall survival and progression-free 
survival among the patients of this study (Table 3 and Table 4, respectively). The 
number of previous treatment also impact on progression-free survival (Table 4). 
Interestingly, we observed that patients with high basal sCD73 enzyme activity 
(>27.8 pmol/min/mg protein) had 6- and 4-fold increased risk of death and 
progression, respectively, when compared with patients with sCD73 enzyme 
activity <27.8 pmol/min/mg protein (Hazard Ratio [HR]=6.27; 95% CI 2.17 – 
18.11; P=0.001 and HR=4.24; 95% CI 1.64 - 10.93; P=0.003, respectively) (Table 
3 and Table 4, respectively). 
Interestingly at multivariate analysis, we found that sCD73 enzyme activity 




























 Univariate Multivariate 
HR (95% CI) P value HR (95% CI) P value 
GENDER (M vs F) 2.08 (0.80-5.38) P=0.13 n.s. 
AGE, years (≥62 vs <62) 1.09 (0.45-2.65) P=0.85 n.s. 
BRAF status (mut vs wt) 0.53 (0.19-1.48) P=0.22 n.s. 
LDH, IU/L(≥480 vs < 
480) 
2.72 (1.07-6.88) P=0.03 n.s. 
LINE OF TREATMENT 
(>2 vs 2) 
2.38 (0.96-5.94) P=0.06 n.s. 
BRAIN METS (yes vs 
no)  
1.04 (0.35-3.12) P=0.94 n.s. 
Basal sCD73 activity 
(≥27.8 vs < 27.8) 
6.27 (2.17-18.11) P=0.001 6.27 (2.17-18.11) P=0.001 
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Table 4_ Analyses of the associations of sCD73 activity and progression-free 
survival 




Abbreviations: HR=hazard ratio; CI=confidence interval; n.s.: not significant; 
M=male; F=female; MUT=mutant; WT=wild-type; LDH=lactate dehydrogenase; 
IU/L: International Units per Liter; METS=metastasis; sCD73=soluble CD73. P 





  Univariate Multivariate 
HR (95% CI) P value HR (95% CI) P value 
GENDER (M vs F) 1.64 (0.73-3.70) P=0.23 n.s. 
AGE, years (≥62 vs <62) 1.30 (0.59-2.89) P=0.52 n.s. 
BRAF status (mut vs wt) 0.72 (0.30-1.69) P=0.45 n.s. 
LDH, IU/L(≥480 vs < 
480) 
2.37 (1.04-5.39) P=0.04 n.s. 
LINE OF TREATMENT 
(>2 vs 2) 
2.34 (1.02-5.34) P=0.04 n.s. 
BRAIN METS (yes vs 
no)  
1.33 (0.53-3.36) P=0.54 n.s. 
Basal sCD73 activity 
(≥27.8 vs < 27.8) 
4.24 (1.64-10.93) P=0.003 4.24 (1.64-10.93) P=0.003 
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4.3.4 Correlation between the sCD73 enzyme activity and clinical response to 
nivolumab in metastatic melanoma patients 
We next found a very novel and interesting association between the response of 
patients to nivolumab and the value of the enzyme activity of sCD73 measured in 
the serum before treatment with nivolumab, compared with patients who do not 
respond to treatment. All patients considered in this study who showed a partial 
response to nivolumab (PR) or stable disease (SD) had low levels of sCD73 
enzyme activity before starting the treatment (Table 5). Accordingly, the disease 
control rate (DCR) to nivolumab, defined as the proportion of patients with CR, 
PR and SD, was significantly associated with low pre-treatment sCD73 enzyme 
activity (<27.8 pmol/min/mg protein) (P= 0.001) (Table 5). Conversely, almost 
half of the patients who progressed (PD) after nivolumab treatment had elevated 
basal sCD73 enzyme activity (Table 5). 
 
Table 5_ Response to treatment related to sCD73 enzyme activity levels 
     
 
Pts: patients; CR: complete response; PR: partial response; SD: stable disease; 
PD: progressive disease; DCR: disease control rate. 
 
These results suggest that basal levels of serum sCD73 enzyme activity could help 






Nivolumab, as other monoclonal antibodies against PD1/PDL1 pathway, 
represents the most effective therapeutics in advanced melanoma to date. The 
identification of biomarkers that predict the clinical response to anti-PD1 drugs 
still remains a challenge for selecting patients for therapy. Compelling evidence 
describe that elevated levels of sCD73 activity and expression have been found in 
the serum of patients with several types of tumor (126, 127) and the expression of 
CD73 within tumor microenvironment is heterogeneous in primary melanomas 
and cutaneous melanoma metastases (12), although elevated tumor levels of 
CD73 have been found in melanoma patients with late-stage disease (128). This 
raise the question whether the increased levels of sCD73 in the serum might have 
a prognostic value extending beyond melanoma to other cancers and if it could 
complement the prognostic value of other biomarkers or histopathologic features 
to guide also the selection of patients for therapy. 
The aim of this study was to identify a potential predictive factor of response to 
immunotherapy by characterizing CD73 enzymatic activity in melanoma patients 
receiving nivolumab. This was a single-center retrospective study that initially 
involved 37 patients. We observed that patients with elevated serum sCD73 
enzyme activity had a significantly increased risk of death and disease progression 
compared to patients with low CD73 enzyme activity. Moreover, we observed 
that the basal activity of sCD73 in the serum, determined before starting 
nivolumab treatment, was elevated in patients who do not respond to nivolumab 
therapy, while patients who benefit from nivolumab treatment had lower levels of 
sCD73 enzyme activity. Interestingly, the levels of sCD73 enzyme activity were 
independent from other variables such as the status of BRAF, the presence of 
brain metastasis and the levels of LDH. Lastly, we did not observe any significant 
difference in the basal sCD73 enzyme activity levels between patients previously 
treated with ipilimumab and those treated with BRAF inhibitors if indicated. 
Certainly, these data need to be validated in a larger and external population to 
establish the best cut-off reference for sCD73 enzymatic activity and its 
specificity for metastatic melanoma to support that, prospectively, CD73 could be 
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used as a biomarker, in addition to known clinical prognostic parameters, in 























In conclusion, I firstly characterized the role of A2BR within tumor-stroma 
focusing my attention on two of the most important cell populations involved in 
tumor growth and angiogenesis: myeloid-derived suppressor cells (MDSCs) and 
cancer-associated fibroblasts (CAFs). I observed that A2BR stimulation 
contributes to the adenosine-mediated immunosuppressive effects, by regulating 
the accumulation of MDSCs within tumor tissue that critically contribute to the 
pro-angiogenic effects of A2BR within tumor microenvironment. In an attempt to 
fully characterize the role of A2BR in the surrounding stroma, I then focused my 
attention also on the activity of stromal fibroblasts within tumor 
microenvironment upon A2BR stimulation. I observed that A2BR stimulation was 
able to modulate the activity of stromal fibroblasts that, in turn, produces tumor-
promoting soluble factors such as FGF-2 and CXCL12 that are critical players in 
immunosuppression and angiogenesis. These results provide new insights into the 
mechanisms through which A2BR regulates intercellular crosstalk in the tumor 
microenvironment. Importantly, pharmacological blockade of A2BR is able to 
significantly limit the tumor growth in vivo, by reducing the accumulation of 
MDSCs, tumor angiogenesis and activation of tumor-associated fibroblasts, 
supporting the therapeutic potential of A2B antagonists as anti-cancer agents.  
 
Secondly, I studied a new immunosuppressive mechanism mediated by A2AR that 
involves Notch signalling pathway in CD8+ T cells. T cells are essential effectors 
of tumor immunity (18) and one of the crucial signalling pathways involved in T-
cell development, lineage selection and activation is Notch (19). Here, we 
observed that A2AR stimulation was associated with reduced Notch1 expression 
and reduced CD8+ T cells functions and these effects were enhanced by inhibiting 
Notch1 signalling. Moreover A2AR stimulation was not effective once the T cell 
receptor (TCR) was activated. The inhibitory effects of A2AR stimulation were 
lost in CD8+ T cells from N1IC mice, in contrast the effects of Notch inhibitor 
occurred in A2AKO CD8+ T cells. This led me to suppose that the inhibitory 
effect of A2AR in CD8+ T cells depends, at least in part, on Notch signalling, but 
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not vice versa.  
 
Finally, I focused my attention on the main ectonucleotidase involved in 
adenosine synthesis, CD73. Nowadays, adenosinergic system plays a pivotal role 
as an anti-tumor therapeutic potential target together with adenosine-generating 
enzymes and possible as predictive factor of response to immunotherapy. We 
evaluated the associations of sCD73 enzyme activity with clinical outcomes of 
patients with metastatic melanoma, receiving nivolumab in a retrospective study. I 
observed that metastatic melanoma patients with high basal serum level of sCD73 
enzyme activity, before starting nivolumab treatment, had a lower response rate to 
nivolumab, shorter survival and higher rates of progression of disease. Patients 
obtaining partial response to nivolumab or stable disease had low levels of sCD73 
activity in the serum. Although these data need to be confirmed and validated, 
they suggest a predictive role for sCD73. Finding new biomarkers that better 
correlate with rates of response to PD-1 blockade is a need for oncologists (149, 
150) these evidence could be very helpful to select patients to an appropriate 
therapy and CD73 monoclonal antibodies could potentially represent a highly 
potent and innovative strategy in combination with currently used 
immunotherapeutic. 
 
Therefore, the adenosinergic system is one of the most important player in 
promoting tumor growth. Since adenosinergic-targeted molecules entered in 
clinical practice for patients with malignancies, understanding the mechanisms by 
which these molecules modulate immune- and stromal-cells responses in the 
tumor environment is important for developing new strategies and/or combined 
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